

# Sri Lanka Dental Journal

Volume 29  
Number 02  
December 2000



**The Official Publication  
of the Sri Lanka Dental Association**

**ISSN 1391-07280**

# ACROSS

A PRACTICAL SUCCESS

SMC  
SONIFORD MAELLER CORP.  
**APOZA**  
ENTERPRISE CO., LTD.

*Opus  
Dent*


The Light Side of Dentistry

 Metrodent



INDUSTRIA ZINGARDI

**ORTHO  
CARE**  
(198) int'l



- ✓ HIGH PERFORMANCE
- ✓ PARTS AVAILABLE
- ✓ INFECTION FREE
- ✓ PRICE AFFORDABLE

SOLE AGENT IN SRI LANKA

 **Nawakrama**

Nawakrama (Pvt.) Ltd.,  
No. 55, Negombo Road, Peliyagoda.

Tel : 074 - 829729 / 01 - 913911 upto 4  
Fax : 074 - 829789 / 01 - 913910  
E mail : nkpl@pan.lk



# Sri Lanka Dental Journal

Volume 29

Number 2

December 2000

The **Sri Lanka Dental Journal** is published biannually by the Sri Lanka Dental Association in collaboration with the College of Dentistry and Stomatology of Sri Lanka, College of General Dental Practitioners of Sri Lanka and the College of Community Dentistry of Sri Lanka.

## Editorial Office

Office of the SLDA,  
Professional Centre,  
275/75, Bauddhaloka Mawatha,  
Colombo - 7.

Correspondence regarding editorial matters, articles, reviews and news items should be addressed to the Editor, SLDJ, Dr. Deepthi Nanayakkara, Dept. of Anatomy, Faculty of Medicine, University of Peradeniya.  
Tele: 08/388315, 388260.

Correspondence regarding advertisements should be addressed to Dr. Ranjith Weerasinghe, Dental Surgery, Y. M. B. A. Building, Dehiwala.  
Tele: 01/713217, 723741.

Correspondence concerning financial matters should be addressed to Dr. Gamini de Silva, 22, Wijerama Mawatha, Colombo - 07.  
Tele: 01/685443, 685755

ISSN 1391 - 0728

© SRI LANKA DENTAL ASSOCIATION

Typesetting & Printed by:  
**AK 2 PRO** - Ethul Kotte, Kotte.  
Tele: 074 - 404002

## CONTENTS

- 57 **Editorial**
- Leading Article**
- 59 *Dental consideration in preventing infective endocarditis*  
M.R. Mohideen
- Review Article**
- 63 *Risk factors for periodontal disease and periodontal disease as a risk factor for systemic conditions*  
A. Tilakaratne
- 69 *Burning Mouth Syndrome*  
S.P.A.G. Ariyawardana
- Research Article**
- 77 *Recurrence of disease and survival of oral cancer patients treated at the Faculty of Dental Sciences, Peradeniya*  
N.A. de S. Amaratunga and J.U. Weerasinghe
- Case Report**
- 84 *Cervical Mucocele – an unusual presentation of a ranula*  
S.P.A.G. Ariyawardana and M.A.M. Sitheeque
- 88 **Instruction for Authors**

**Dentsply Asia**

25/F, Lee Chang Hong Centre,  
65 Wong Chuk Hang Road,  
Aberdeen, Hong Kong.  
Tel: (852) 2870 0336  
Fax: (852) 2879 0620  
E-mail: [business@dentsply-asia.com](mailto:business@dentsply-asia.com)  
Web site: [www.dentsply.com](http://www.dentsply.com)

**Dentsply Offices**

Taiwan, China (86-22) 2532-9362  
India (91-11) 647-6040  
Korea (82-2) 577-3797  
Philippines (65-2) 890-7643  
Taiwan (886-2) 2223-7777  
Thailand (66-2) 295-3744  
Vietnam (84-8) 823-8116  
Indonesia (62-21) 343-1070

**Dentsply's Authorized Dealers**

Malaysia NK Taek (60-3) 230-9622  
Singapore SA Dental (65) 334-5228  
Global Dental (852) 2598-9788  
Hong Kong Win Trading (852) 2593-0994  
Myanmar Win Trading (95-11) 453-0994  
Sri Lanka Enso Ltd. (94-11) 447-325

**DENTSPLY**  
ASIA

**Esthet-X™**  
micro matrix restorative

*Build More Than a Restoration. Build a Reputation.*

*The most complete esthetics  
restorative system available*

*Micro Matrix technology*

*A brilliant, durable polish  
comparable to microfills\**

*Physical properties of an  
advanced hybrid composite*

*Non-sticky handling*


*Resists slumping  
& sculpts beautifully*

*Optical quality to  
match natural tooth structure*

*31 shades in 3 different opacities  
to build the most natural-looking  
teeth "from the inside out"*

*Esthet-X™ TruMatch™ Shade Guide for easy,  
accurate color matching*

*To learn more about Esthet-X™ Micro Matrix Restorative,  
contact your local Dentsply office or dealers, or visit [www.eshet-x.de](http://www.eshet-x.de)*



Esthetics so good, they'll think you walk on water.



# Sri Lanka Dental Journal

Volume 29

Number 2

December 2000

## Editor

Deepthi Nanayakkara  
*BDS, PhD (SL)*

## Assistant Editors

K. Krishnarasa  
*LDS, DDPHRCs (Eng)*

S.P.A.G. Ariyawardene  
*BDS, MS (SL)*

B.G. Nanayakkara.  
*BDS, PhD (SL)*

V.S. Weerasinghe  
*BDS, MPhil (SL), PhD (UK)*

## Finance Manager

Gamini de Silva  
*BDS, FFDRCS (Ire)*

## Editorial Board

A.N.I. Ekanayake  
*BDS, DDPHRCs (Eng), PhD (London)*

N.A.de S. Amarathunga  
*BDS, FDSRCS (Eng), PhD (SL)*

B.R.R.N. Mendis  
*BDS, PhD (Bristol), FDSRCS  
(Eng & Edin), FFDRCS (Ire)*

M.T.M. Jiffry  
*BDS, MMed.Sc(SL), MSc(Bristol), FI(Biol)*

M.S. Chandrasekera  
*BDS, PhD (UK)*

L.P. Samaranyake  
*BDS, DDS, FRC Path, MI Biol, FHKC (Path),  
FHKAM (Dental Surgery)*

N. Aturaliya  
*MBBS, MRCP (UK)*

M.A.M. Sitheequ  
*BDS, FDSRCS (Glas)*

## EDITORIAL

### The aspiring dental student: his future

Serious concern has been expressed over the problem of non-availability of employment for the newly qualified dental graduates in the Ministry of Health. While three batches of newly passed out dental graduates are facing a great crisis in their career, as the State is unable to provide them with employment in the Ministry of Health, a group of aspiring dental students are longing to commence their journey towards their chosen career in dentistry at the Faculty of Dental Sciences of the University of Peradeniya.

But how are our students chosen? The selection of students to the Faculty of Dental Sciences is based purely on their intellectual abilities as measured by their achievements at the GCE Advanced Level examination.

In the year 1999, approximately 25000 students sat for this examination in the bio- sciences stream. About 7000 of this number have been successful in securing the obligatory entry requirement to the universities. All 75 students who are enrolling with the study programme in Dentistry have been chosen on a district quota basis in the bio-sciences stream having obtained the minimum cut off point mark.

Clinical dentistry requires manipulative skills. Does this particular selection procedure help us to pick out a student who is particularly 'good with his hands'? The answer to this question is No. We on the other hand are picking out good examination students possibly highly intelligent, some of whom are deficient in manual dexterity. The latter student has little chances of making a successful career in dentistry except in a rare non-clinical area.

It is equally important to find out the attitudes of these undergraduates towards the dental profession and also the factors that prompted them to select a career in dentistry. In this respect, the results of a survey that has been carried out amongst the first year dental undergraduates by a group of academics will be most welcomed when it is published in the Sri Lanka Dental Journal in due course. Studies done in the West have shown that common reasons for choosing dentistry as a career include a positive public perception of the profession due to above average financial benefits and high public esteem.

Anyhow, to be successful in dentistry, one should possess an above average intelligence and manual dexterity to a moderate degree. They should also be kind and compassionate towards others. Those graduates opting to join general dental practice should have management skills, and a business sense if they are to be successful in the highly competitive market.

In order to attract the intelligent young ones of today the career prospects and employment avenues should be satisfactorily diverse and stimulating.

Deepthi Nanayakkara  
Editor

**LEADING ARTICLE****Dental consideration in preventing infective endocarditis****M.R. Mohideen***Department of Medicine, Faculty of Medicine, University of Ruhuna*

Infective endocarditis is a life threatening medical condition with an incidence ranging from 10 to 60 cases per million persons per year.<sup>(1,2)</sup> Though in the majority of instances it is an infection of the endocardial surface of the heart, structures outside the heart such as arteriovenous shunts, arterioarterial shunts may also be affected. Before the availability of antimicrobial agents, the mortality rate was 100%.<sup>(3)</sup> The mortality rate remains at a high level despite the availability of potent antimicrobial agents but has substantially improved with optimal treatment.<sup>(4)</sup> Early diagnosis is the single factor that is likely to improve the outcome. Because of its severity, it is agreed that infective endocarditis should be prevented whenever possible.

A number of prerequisites are necessary for the development of this condition. The main factors that play roles in the acquisition of endocarditis are a suitable cardiac lesion and a source of infection. One of these factors alone is insufficient to cause endocarditis. The endocardial surface should be altered to enable the attachment and colonization of microorganisms. Turbulence of blood and mechanical stress exerted on the endocardial surfaces play a key role in the deposition of platelets and fibrin on these surfaces. High velocity flow favours endothelial deposition of organisms as compared to low velocity flow. Thus left sided cardiac lesions such as mitral and aortic valve disease, ventricular septal defects and patent ductus arteriosus are particularly at risk.<sup>(5)</sup> Further deposition of fibrin and platelets causes creation of vegetation, resulting in a condition called

nonbacterial thrombotic endocarditis. The vegetation serves as the nidus for bacterial invasion. Bacteria then reach this site and colonise prior to further multiplication beneath a protective covering of fibrin and platelets.

While virtually any bacterial organism can cause bacterial endocarditis, the vast majority of infections are caused by gram-positive cocci. The viridans group of streptococci is the most common cause of endocarditis involving native heart valves, in patients with congenital heart disease and in those who are not injection drug users.<sup>(6)</sup> Coagulase - positive staphylococci (*Staphylococcus aureus*) commonly cause bacterial endocarditis in patients with prosthetic valves and in injection drug users.<sup>(7)</sup> Presence of these organisms is also a common cause of acute bacterial endocarditis in persons whose heart valves were previously normal.

The ability of certain organisms to adhere avidly to the platelet - fibrin matrix explains why streptococci, staphylococci and enterococci are particularly common in infective endocarditis. Among the proposed pathogenetic mechanisms, the ability to elaborate the complex polysaccharide dextran appears to be critical factor at least in the streptococci. In others, platelet aggregability of the platelets may be an important factor.<sup>(8)</sup>

Bacteraemia plays a critical role in the development of endocarditis and the likelihood of it occurring forms an important basis of recommendations on prophylaxis. Bacteremia may occur spontaneously

such as through food chewing or tooth brushing, or it may develop as a complication of a focal infection, such as a periodontal or periapical infection, a urinary tract infection, pneumonia or cellulitis. Selected surgical and dental procedures and instrumentations, especially those involving mucosal surfaces or contaminated tissue, can cause a transient bacteremia that rarely persists for more than a few minutes.

The incidence of transient bacteremia after various dental procedures has been extensively studied.<sup>(9)</sup> Both the incidence and the magnitude of bacteremias of oral origin are proportional to the degree of oral inflammation and infection.<sup>(10)</sup> Extraction of one or more teeth, dental implant placement and reimplantation of avulsed teeth, periodontal surgery and prophylactic cleaning of teeth or implants, where bleeding is anticipated are examples of high risk procedures associated with significant transient bacteremia.<sup>(11)</sup> Placement of removable prosthodontic or orthodontic appliances, oral impressions, fluoride treatment, oral radiographs and orthodontic appliance adjustment are considered low risk procedures that require no prophylactic antibiotics.<sup>(11)</sup>

The issue is complicated by the fact that data on postprocedure bleeding and bacteremia show that there is no relationship between bleeding and bacteremia.<sup>(12)</sup> Significant bacteremia can occur in the absence of clinically discernible bleeding. The intensity of bacteremia in humans is significantly less than that used in experimental endocarditis models. It is unlikely that the intensity of bacteremia following dental procedures in children could readily lead to endocarditis.<sup>(12)</sup> A study among children randomised to either tooth brushing, scaling or professional cleaning showed equal chance of the likelihood to develop odontogenic bacteremia from tooth brushing at home as from professional scaling and polishing of the teeth at dental surgery.<sup>(13)</sup>

The cumulative exposure to bacteremia is significantly greater from everyday procedures when compared to dental operative procedures. It is far more likely that such everyday procedures are the cause of bacterial endocarditis because the cumulative exposure is often hundreds, thousands, or even millions of times greater than that occurring following surgical procedures such as extraction of teeth. The presence of certain bacterial species in blood may be more important than the overall frequency of bacteremia.

The degree to which the patient's underlying condition creates a risk of endocarditis should also be taken into consideration. Endocarditis is associated with some cardiac conditions more often than with others. These conditions are stratified into high, moderate and negligible-risk categories based primarily on the potential outcome if endocarditis occurs. The high-risk category includes individuals with prosthetic heart valves, a history of endocarditis, complex cyanotic congenital heart disease, or surgically constructed systemic pulmonary shunts or conduits.<sup>(5)</sup> The moderate risk category includes patients with congenital cardiac malformations (other than complex cyanotic disease), acquired valvular dysfunction (e.g. due to rheumatic fever), hypertrophic cardiomyopathy, mitral valve prolapse with valvular regurgitation and/or thickened leaflets, and certain types of heart murmurs. Individuals with isolated secundum atrial septal defects, surgical repair of atrial or ventricular septal defects, coronary bypass surgery, mitral valve prolapse without valvular regurgitation, innocent or physiological heart murmurs, previous Kawasaki disease or rheumatic fever without valvular dysfunction, and pacemakers do not necessarily need antibiotic prophylaxis.<sup>(14)</sup> The negligible-risk category suggests that endocarditis develops no more often than in the general population.

### Dental consideration in preventing infective endocarditis

Antibiotic prophylaxis in at-risk patients has been accepted as reasonable practice for four decades, although data confirming its effectiveness are lacking.<sup>(15)</sup> While there are currently no carefully controlled studies to prove antibiotic prophylaxis helps protect against endocarditis, *in vitro* bacteria studies, experimental animal models, uncontrolled clinical observations and retrospective analysis of human antibiotic use provided the basis of guidelines recommended for prevention of bacterial endocarditis.<sup>(16)</sup> However, with little convincing evidence from human studies, expert groups continue to specify antibiotic prophylactic regimens.

Two important outcome studies that have been recently published have reopened the debate on endocarditis prophylaxis. These two outcome-based studies have similar findings and indicate that the current guidelines, which are not based on population-based outcome studies, require further review.

A Dutch study<sup>(1)</sup> assessed 427 patients with endocarditis and found that 64% of these patients would have been eligible for antibiotic prophylaxis based on previously known cardiac conditions. Twenty-three per cent had undergone a procedure that would have indicated prophylaxis within one-half year of onset of endocarditis, and 11% had undergone a procedure within 30 days of onset. Antibiotic prophylaxis had been administered to 26.6 % of the 64 patients and to 25.8 % of the 31 patients. It was thought that prophylaxis may have prevented 17% of cases within 180 days of onset, a period of time that extends beyond what many believe to be the appropriate incubation period, and 11% of cases within 30 days, representing only 5.3% of cases. Therefore, even if antibiotic prophylaxis was 100% effective and was provided for all at-risk patients receiving dental treatment, only a small fraction of cases of endocarditis (5.3%) would be potentially prevented.

The other study assessed patients in 54 hospitals in the Philadelphia area.<sup>(17)</sup> A total of 287 cases of endocarditis were identified. It was found that in the three months preceding the diagnosis of endocarditis, dental treatment was no more frequent in these patients than in non-infected age- and sex-matched control patients

However, the American Dental Association, like the American Heart Association, believes its current recommendations for endocarditis prophylaxis are valid and that modifications are not indicated at this time. They acknowledge that further research is warranted to determine whether some heart or valvular conditions would require coverage with pre-procedural antibiotics while others would be precluded.

Failure of protection may also occur due to antibiotics starting too early, using inadequate doses, disregarding the use in children and withholding in rheumatic fever patients in the belief that penicillin prophylaxis provides adequate protection when in fact it is insufficient. Prophylaxis fails even with antibiotic regimens recommended by the American Heart Association /American Dental Association.<sup>(11)</sup>

Experiences from dental practices has been shown to be varied and in conflict with guideline recommendation as to endocarditis prophylaxis prior to dental procedures.<sup>(18)</sup> When patients are diagnosed with a cardiac disorder, which predisposes to infective endocarditis they should have a dental examination as soon as possible. Much more importance should be given, however, to encouraging people to seek better routine dental care.

Infective endocarditis represents one of the few potentially fatal infections that may be caused in the patient by a dentist. It is desirable that guidelines for therapy be based on outcome

studies and on evidence of safety, efficacy and, increasingly, cost effectiveness as this disease still produces considerable morbidity and mortality. In spite of the uncertainty that elimination of all cases due to such procedures would be small, and the risk for adverse reactions, including anaphylaxis, and the possible occurrence of drug-resistant organisms the other reason to adhere to guidelines laid down by organizations is the threat of litigation for failure to provide prophylactic treatment.

The emerging data on infective endocarditis, suggesting limited risk associated with certain dental treatment, the time of incubation and the increasingly available outcome-based evidence, require continual review of the current historically and empirically based recommendations.

### References

1. Van der Meer JTM, Thompson J, Valkenburg HA, et al. Epidemiology of bacterial endocarditis in the Netherlands. *Arch Intern Med* 1992; 152:1863-73.
2. Pogrel MA, Welsby PD. The dentist and prevention of infective endocarditis. *Br Dent J* 1975;139: 12-6
3. Robinson MJ, Ruedy J. Sequale of bacterial endocarditis. *Am J Med* 1962;32:922-8
4. Bayliss R, Clark C, Oakely CM et al. Incidence, mortality and prevention of infective endocarditis. *J R Coll Physicians Lond* 1986; 20: 15
5. Steckelberg JM, Wilson WR. Risk factors for infective endocarditis. *Infect Dis Clin North Am* 1993;7:9-19.
6. Griffin MR, Wilson WR, Edwards WD, et al. Infective endocarditis. Olmstead County, Minnesota, 1950 through 1981. *JAMA* 1985;254:1199-202.
7. Chambers HF, Korzeniowski OM, Sande MA. *Staphylococcus aureus* endocarditis: clinical manifestations in addicts and nonaddicts. *Medicine* 1983;62:170-7.
8. Gibbons RJ, Nygaard M. Synthesis on insoluble dextran and its significance in the formation of gelatinous deposits by plaque forming streptococci. *Arch Oral Biol* 1968;13; 1249
9. Everett ED, Hirschmann JV Transient bacteremia and endocarditis prophylaxis: a review. *Medicine* 1977;56:61-77
10. Bender IB, Naidorf IJ, Garvey GJ Bacterial endocarditis: a consideration for physicians and dentists. *J Am Dent Assoc* 1984;109:415-420.
11. Adnan S, Dajani, Kathryn A, Taubert, Walter Wilson et. al Prevention of bacterial endocarditis: Recommendations by the American Heart Association *JAMA* 1997;277:1794-1801
12. Roberts GJ Dentists are innocent! "Everyday" bacteremia is the real culprit: a review and assessment of the evidence that dental surgical procedures are a principal cause of bacterial endocarditis in children. *Pediatr Cardiol* 1999;20(5): 317-25
13. Lucas V, Roberts GJ. Odontogenic bacteremia following tooth cleaning procedures in children. *Pediatr Dent* 2000;22(2): 96-100.
14. Gersony WM, Hayes CJ, Driscoll DJ, et al. Bacterial endocarditis in patients with aortic stenosis, pulmonary stenosis, or ventricular septal defect. *Circulation* 1993;87(suppl I): 121-126.
15. Durack DT. Current issues in prevention of infective endocarditis. *Am J Med* 1987;78:149-56
16. Garrod LP, Watworth PM. The risk of dental extraction during penicillin treatment. *Br Heart J* 1962;24: 39-46.
17. Strom BL, Abrutyn E, Berlin JA, et. al. Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. *Ann Intern Med* 1988;129: 761-9
18. Gutschik E, Lippert S. Dental procedures and endocarditis prophylaxis: experiences from 108 dental practices. *Scand J Dent Res* 1990;98(2):144-8

## REVIEW ARTICLES

### Risk factors for periodontal disease and periodontal disease as a risk factor for systemic conditions

A. Tilakaratne

Department of Oral Medicine & Periodontology, Faculty of Dental Sciences, University of Peradeniya

#### Introduction

It is now known that periodontal diseases are infections caused by bacteria and are multifactorial in origin. There are known risk factors that modify or aggravate the existing periodontal diseases. Although the medical researchers have worked steadily for decades to identify risk factors, it is only within the last 5 to 10 years have the dental researchers begun to look for risk factors apart from poor oral hygiene habits which may predispose a person to develop periodontal disease.<sup>(1)</sup>

The American Academy of Periodontology<sup>(2)</sup> indicates that the initial therapy for patients with advanced loss of periodontal support should include the elimination, alteration or control of risk factors that may contribute to periodontitis. Therefore the control of the risk factors involved in periodontal disease is considered to be of utmost importance in the optimal management of periodontal diseases. Diabetes mellitus, infection with human immuno-deficiency virus (HIV), physiological conditions such as pregnancy and menopause which lead to a hormonal imbalance, and the use of certain medications are known to be possible risk factors in periodontal disease. Therefore, the management of risk factors, along with antiinfective and regenerative therapy could be suggested as the most successful approach in the management of periodontitis in the future.

Periodontal diseases can also be a risk factor for other systemic diseases such as cardio-vascular disorders. A link between periodontal diseases with

an increased risk for atherosclerosis and thromboembolism has been shown.<sup>(3)</sup>

Periodontal infections in pregnant women are now being recognized as a risk factor to have pre-term low birth weight (PLBW) babies. PLBW caused by infections is thought to be mediated by the translocation of bacterial products and by maternally produced inflammatory mediators.<sup>(4)</sup>

#### Risk factors for periodontal disease

These can either be systemic factors such as diabetes, HIV infection or local factors such as smoking.

##### 1) Diabetes mellitus

Both insulin-dependent (IDDM) and non-insulin-dependent diabetes mellitus (NIDDM), especially in the long-term are now viewed as significant risk factors for periodontal diseases. These findings were based on the epidemiological studies carried out in the recent past. In a longitudinal study it was found that the age and gender adjusted incidence of periodontal disease in patients with NIDDM was 78 cases per 1000 persons, about three times higher than in those without diabetes (29 cases per 1000 persons).<sup>(5)</sup> It is also known that patients with IDDM or NIDDM are at equal risk for developing periodontal diseases when other variables are controlled. Periodontitis progresses more rapidly and leads to more tooth loss in patients whose diabetes is poorly controlled.<sup>(6)</sup> These patients exhibit higher levels of the enzyme beta-glucuronidase in their gingival crevicular fluid than those in well-controlled

diabetes. It is still not very clear why diabetics increase the risk for severe periodontitis, although increased susceptibility to infection and impaired host response are likely factors. There are no significant differences in the micro-flora between people with either IDDM or NIDDM and those without.<sup>(7)</sup> In diabetics, especially in those whom the disease is poorly controlled or of long duration, the basement membrane of the small vessels thickens as a result of the nonenzymatic glycosylation of extracellular matrix components and intracellular proteins and there is a subsequent accumulation of deposits known as advanced glycosylation end products (AGEs), in vessel walls and on the luminal surface. These changes can narrow the lumen of the vessel interfering with transport across the vessel wall, imparting oxidant stress on the periodontal tissues and prolonging inflammation. This effect could be related to the increased incidence of periodontal disease in diabetics.<sup>(8)</sup> A build-up of AGEs may lead to the microvascular complications seen in diabetes which is a factor in other diabetic complications such as retinopathy, neuropathy and nephropathy.<sup>(9)</sup> There are other suggested mechanisms involved with diabetes, such as vascular changes, polymorphonuclear leukocyte dysfunction, abnormal collagen synthesis, abnormal bone matrix production and inflammatory mediator production, and an altered immune regulation which may have a role in complications of diabetes.<sup>(10)</sup>

It is reported that well-controlled diabetics who receive regular periodontal maintenance care, with good oral hygiene habits are less likely to develop severe periodontitis. Well-controlled diabetics have also been shown to respond to periodontal therapy as equally well as non-diabetics.<sup>(11)</sup>

## 2) HIV (Human Immuno-deficiency Virus) infection

This is a known risk factor for periodontitis. A well designed, 20-month study that included 114 men

showed that the periodontal changes were related to HIV-1 serostatus, immunostatus, age and plaque deposits. The immunosuppression levels of helper-inducer T-cell (CD-4) counts of less than 200, especially in subjects of over 35 years of age. The risk for a greater than 3-mm clinical attachment loss was increased by more than 600%. Further, seropositivity, despite the immunostatus was a significant risk factor for gingivitis.<sup>(12)</sup> An estimated 5% of HIV patients develop a severe, rapidly progressing form of periodontitis or necrotizing ulcerative periodontitis (NUP). This lesion is associated with pronounced immunosuppression. Many of these cases do not respond to standard periodontal therapies, but when they are left untreated NUP can progress to necrotizing stomatitis.<sup>(2)</sup>

The regulation of polymorphonuclear leukocyte (PMN) recruitment into the gingival crevice is hindered in HIV-seropositive patients. This irregular PMN activity may also allow candida organisms to colonize subgingivally and thus increase the likelihood of developing periodontitis.<sup>(13)</sup>

Not only HIV infection, any condition that compromises host defense mechanisms, including irradiation and genetically transmitted diseases predispose patients to early-onset severe periodontitis.

## 3) Age

It has been found that the prevalence of periodontal disease increases with age. It is not clear whether this is the result of accumulating periodontal lesions over the years or to a greater susceptibility of the elderly to develop the disease. Some cross-sectional studies implicate age as a predisposing factor to periodontal disease. According to longitudinal studies, periodontal disease appears to be age-associated rather than to have a direct consequence with the body's

aging process. In a study using 14,690 Americans aged 15 to 74 years, 95% of them who maintained good oral hygiene did not have periodontitis regardless of age.<sup>(14)</sup> It has been documented that periodontitis frequently begins with loss of attachment during youth and early adulthood rather than in the older years.<sup>(15)</sup>

#### 4) Osteoporosis

A relationship between osteoporosis and periodontitis has long been suspected. Oral bone loss associated with osteoporosis may be important in creating a susceptible host for dental disease.<sup>(1)</sup> There is a strong correlation between dental bone mass and the total bone mass among women, as well as total bone mass and number of teeth present in the mouth. Factors such as smoking, which predispose patients to osteoporosis also predispose them to alveolar bone loss.<sup>(16)</sup>

#### 5) Menopause

The dwindling oestrogen levels that follow menopause are known to be linked to a greater risk of tooth loss. In the Nurses Health Study, carried out in the United States of America in 1996, it was found that decreased oestrogen levels in postmenopausal women who did not undergo hormone replacement therapy were associated with significantly greater tooth loss.<sup>(17)</sup> Similarly, in the Leisure World Study in 1995 which aimed to find out the benefits of oestrogen replacement therapy on oral health, it was found that women who received oestrogen replacement therapy had a lower risk for edentulism.<sup>(18)</sup>

It has been shown that bisphosphonate alendronate, an approved drug in the treatment of osteoporosis could lower the risk of bone height and density loss.<sup>(19)</sup>

#### 6) Increased use of medications

More people are now using one or more prescriptive or over-the-counter medications than in the past. These may also affect the periodontal health. For example, some medications significantly decrease the salivary flow. These include anti-hypertensive drugs, narcotic analgesics, some sedatives, tranquilizers and antihistamines. The resulting xerostomia can help to accumulate more plaque. Other drugs, particularly those in liquid or chewable form that contain added sugar alter the pH and composition of plaque, making it more adherent to tooth surfaces.<sup>(1)</sup>

#### 7) Smoking

Tobacco smoking is a highly predictive risk factor for periodontal disease, especially for severe periodontitis. It was found that light smokers (aged 25-74 years) had a relative risk of developing detectable periodontal disease that was 2 times higher than non-smokers, and heavy smokers had a relative risk that was 7 times higher.<sup>(20, 21)</sup>

There are a number of suggested mechanisms by which smoking may promote periodontal disease. Periodontal pathogens such as *Bacteroides forsythus* and *Porphyromonas gingivalis* could persist after mechanical debridement to a larger degree in smokers than nonsmokers.<sup>(21)</sup> Smoking has been shown to decrease both cell-mediated and humoral immune responses. Peripheral blood polymorphonuclear leukocyte phagocytosis is significantly impaired in smokers and they have lower levels of serum IgG<sub>2</sub>, which normally provides the predominant serum antibody response to antigens of both *Actinobacillus actinomycetemcomitans* and *Porphyromonas gingivalis*.<sup>(22, 23)</sup> One study has also shown that even passive smoking can over-stimulate oral PMN function for up to an hour after exposure to smoke, although it is not known how detrimental that effect might be cumulatively.<sup>(24)</sup> Smoking cessation seems to yield marked periodontal

benefits. It was found that, within a few months of quitting, the gingival inflammation of smokers worsens and bleeding is common during brushing for several months. After about a year, the gingival tissues may revert from a thickened fibrotic appearance customarily found in smokers to normal anatomy and contour.<sup>(25)</sup>

#### 8) Other systemic factors

Some studies suggest that chronic stress, depression, financial problems, social isolation and other anxiety related psychosocial factors may be risk factors for periodontitis.<sup>(26, 27)</sup>

It is suggested that these stressors could depress the body's immune responsiveness to periodontal pathogens and thus increase the likelihood and severity of periodontal disease.

Alcohol abuse has also been suspected to have contributory effects on periodontal disease. However, further studies may be needed to confirm this. Other possible systemic factors that may increase the risk include a family history of periodontitis and certain genetic diseases.

### ***Periodontal diseases as a risk factor for other systemic conditions***

Periodontal disease may itself be a risk factor for other infections in the body, systemic diseases and pregnancy-related problems.

#### 1) Cardio-vascular disease (CVD)

In recent years several researchers have found evidence linking periodontal disease with an increased risk for atherosclerosis and thromboembolism, independent of other risk factors for CVD. In a study adjusted for other risk factors of coronary heart disease (CHD), the researchers found that men with periodontitis were 25% more likely to develop CHD. The risk was particularly high for men under the age of 50, who

had a relative risk for CHD.<sup>(3)</sup> In two different surveys, Umino and Nagao found heart disease to be the most common condition shared by patients with periodontitis.<sup>(28)</sup>

Given that periodontal disease is a chronic infectious disease that involves an abundance of gram negative species containing endotoxins and pro-inflammatory cytokines, it is not impossible that it may pose systemic challenges that predispose the periodontitis patient to coronary heart disease or exacerbate the condition.<sup>(1)</sup> Some authors suggest that microbial pathogens associated with chronic infections such as periodontal disease may disseminate through blood to infect the vascular endothelium.<sup>(1)</sup> Further, myocardial ischemia often is preceded by acute thromboembolic events, and several major species of dental plaque, such as *Streptococcus sanguis* have been shown to induce thrombosis.<sup>(29)</sup>

Periodontal disease may also interfere with blood lipid metabolism. Although the data show a consistent link between periodontal disease and CVD, there is still only limited evidence for a causal relationship.<sup>(30)</sup>

#### 2) Pre-term low birth weight children

Although the infant mortality rate has decreased significantly since the mid 1960s, pre-term low birth weight (PLBW) babies are still common even in developed countries such as the United States, despite improved prenatal care. Even when traditionally believed risk factors for PLBW such as smoking, drug and alcohol abuse, nutrition are taken into account, about 25% of PLBW cases occur in women without these risk factors.<sup>(4)</sup> Since PLBW is a significant factor for infant mortality, there appears to be a great need to investigate for further causes of PLBW.

Periodontal infections in pregnant women are receiving considerable attention as a potential

independent risk factor for PLBW infants. Studies have demonstrated a link between genitourinary infection and PLBW, and the widely held opinion is that PLBW caused by infections is probably mediated by the translocation of bacterial products, such as endotoxins associated with periodontal disease, and by maternally produced inflammatory mediators.<sup>(4)</sup>

Periodontal infections which serve as reservoirs for gram negative anaerobic organisms, lipopolysaccharides, and inflammatory mediators may also threaten the health of the fetoplacental unit. This has been demonstrated in some animal studies. For instance, in one study the fetuses of hamsters with localized subgingival infections of a common periodontal pathogen weighed up to 25% less than the fetuses of healthy pregnant hamsters. These infections were also associated with increases in inflammatory mediators that appear to retard fetal growth.<sup>(31)</sup> A few human studies too show a similar link to this. In a study of 124 pregnant or postpartum mothers, controlled for traditional well known factors of low birth weight babies, Offenbacher et al.<sup>(32)</sup> found that those with periodontal disease were seven times more likely to deliver a PLBW baby. Hill<sup>(33)</sup>, in 1997 reported that *Fusobacterium nucleatum* is the most frequent isolate cultured from the amniotic fluid of women with preterm labor, but that this organism is not prevalent in the vaginal microflora. It is commonly found in the mouth, however, and the authors theorize that it may spread to the amniotic fluid via a transient bacteremia in the presence of periodontal disease.<sup>(33)</sup>

### 3) Other systemic conditions

Periodontal disease, particularly in hospitalized patients or those in nursing homes may increase the risk for bacterial pneumonia, because dental plaque among these patients tends to harbor a high number of respiratory pathogens.<sup>(34)</sup> It was also noted that the elderly people who undergo

prosthetic joint replacement are at a greater risk of developing infections in the prostheses as a consequence of untreated dental disease. This was thought to be due to the etiologic bacteria entering the bloodstream in the oral cavity.<sup>(35, 36)</sup>


### References

1. Cohen DW and Rose LF. The Periodontal-medical Risk Relationship. Compendium / Special issue. 1998; 19: 11-24.
2. American Academy of Periodontology, Committee on Research, Science and Therapy. Periodontal considerations in the HIV positive patient. Chicago, The American Academy of Periodontology, 1994.
3. DeStefano F, Anda RF, Kahn HS. Dental disease and risk of coronary heart disease and mortality. *Br Med J* 1993; 306: 688-691.
4. Gibbs RS, Romero R, Hillier SL. A review of premature birth and subclinical infections. *Am J Obstet Gynecol* 1992; 166: 1515-1528.
5. Emrich LJ, Shlossman M and Genco RJ. Periodontal disease in non-insulin-dependent diabetes mellitus. *J Periodontol* 1991; 62: 123-130.
6. Seppala B, Seppala M and Ainamo J. A longitudinal study on insulin-dependent diabetes mellitus and periodontal disease. *J Clin Periodontol* 1993; 20: 161-165.
7. Tervonen T, Oliver RC, Wolff LF. Prevalence of periodontal pathogens with varying metabolic control of diabetes mellitus. *J Clin Periodontol* 1994; 21: 375-379.
8. Schmidt AM, Weidman E, Lalla E. Advanced glycation end product (AGEs) induces oxidant stress in the gingiva: A potential mechanism underlying accelerated periodontal disease associated with diabetes. *J Periodontal Res* 1996; 31: 508-515.
9. Brownlee M. Glycation and diabetic complications. *Diabetes*. 1994; 43: 836-841.
10. Cutler CW, Eke P, Arnold RR. Defective neutrophil function in an insulin-dependent diabetes mellitus patient: a case report. *J Periodontol* 1991; 62: 394-401.
11. Grosai SG, Skrepcinski FB, DeCaro T. Responses to periodontal therapy in diabetics and smokers. *J Periodontol* 1996; 67: (suppl.): 1094-1102.

12. Barr CC, Lopez MR, Rua-Dobles A. Periodontal changes by HIV serostatus in a cohort of homosexual and bisexual men. *J Clin Periodontol* 1992; 19: 794-801.
13. Lamster IB, Grahic JT, Mitchell-Lewis DM. Periodontal manifestations of HIV infection. Presented at the 1997 Sunstar- Chapel Hill Symposium on Periodontal Diseases and Human Health, March 24-25, 1997; Chapel Hill, NC.
14. Abdellatif HM and Burt BA. An epidemiological investigation into the relative importance of age and oral hygiene status as determinants of periodontitis. *J Dent Res* 1987; 66: 13-18.
15. Van der Velden U. The onset age of periodontal destruction. *J Clin Periodontol* 1991; 18: 380-383.
16. Jeffcoat MK and Chestnut CH. Systemic osteoporosis and oral bone loss: evidence shows increased risk factors. *J Am Dent Assoc* 1993; 56: 124-149.
17. Grodstein F, Colditz GA and Stampfer DJ. Post-menopausal hormone use and tooth loss: a prospective study. *J Am Dent Assoc* 1996; 127: 370-377.
18. Pagaini-Hill A. The benefits of oestrogen replacement therapy on oral health: the Leisure World cohort. *Arch Intern Med* 1995; 155: 2325-2329.
19. Jeffcoat MK and Reddy MK. Systemic osteoporosis and oral bone loss. Presented at the 1997 Sunstar – Chapel Hill Symposium on periodontal Diseases and Human Health, March 24-25, 1997; Chapel-Hill, NC.
20. Grossi SG, Zambon JJ, Ho AW. Assessment of risk for periodontal disease. I. Risk indicators for attachment loss. *J Periodontol* 1994; 65: 260-267.
21. Grossi SG, Genoa RS, Machtei EE. Assessment of risk for periodontal disease. II. Risk indicators for alveolar bone loss. *J Periodontol* 1995; 66: 23-29.
22. MacFarlane GD, Herzberg MC, Wolff LF. Refractory periodontitis associated with abnormal polymorphonuclear leukocyte phagocytosis and cigarette smoking. *J Periodontol* 1992; 63: 908-913.
23. Tew JG, Zhang JB, Quinn S. Antibody of the IgG2 subclass, *Actinobacillus actinomycetemcomitans*, and early-onset periodontitis. *J Periodontol* 1996; 67 (suppl): 317-322.
24. Numabe Y, Ogawa T, Kamoi T. Alterations in PMN function after smoking and passive smoking. Presented at the 1997 Sunstar- Chapel Hill Symposium on Periodontal Diseases and Human Health, March 24-25, 1997; Chapel Hill, NC.
25. Haber J. Smoking is a major risk factor for periodontitis. *Curr Opin Periodontol* 1996; 23: 289-292.
26. Moss ME, Beck JD, Kaplan BH. Exploratory case-control analysis of psycho-social factors and adult periodontitis. *J Periodontol* 1996; 67: 1060-1069.
27. Marcenes WS and Sheiham A. The relationship between work stress and oral health status. *Soc Sci Med* 1992; 35: 1511-1520.
28. Umino M and Nagao M. Systemic diseases in elderly dental patients. *Int Dent J* 1993; 43: 213-218.
29. Herzberg MC, MacFarlane GD and Gong K. The platelet interactivity phenotype of *Streptococcus sanguis* influences the course of experimental endocarditis. *Infect Immun* 1992; 60: 4809-4818.
30. Moreillon P, Overholzer CD, Malinverni R. Predictors of endocarditis in isolates from cultures of blood following dental extractions in rats with periodontal disease. *J Infect Dis* 1988; 157: 990-995.
31. Collins JG, Windley HW, Arnold RR. Effects of *Porphyromonas gingivalis* infection on inflammatory mediator response and pregnancy outcome in the hamster. *Infect Immun* 1994; 62: 4356-4361.
32. Offenbacher S, Katz V, Fertik G. Periodontal infection as a possible risk factor for preterm low birth weight. *J Periodontol* 1996; 67: 1103-1113.
33. Hill GB. Update on the role of microbial infections in preterm birth. Presented at the 1997 Sunstar-Chapel Hill Symposium on Periodontal Diseases and Human Health, March 24-25, 1997; Chapel Hill, NC.
34. Scannapieco FA and Mylotte JM. Relationships between periodontal disease and bacterial pneumonia. *J Periodontol* 1996; 67: 1114-1122.
35. Jacobsan JJ, Schweitzer S, DePorter DJ. Chemoprophylaxis of dental patients with prosthetic joints: a simulation model. *J Dent Educ* 1988; 52: 599-604.
36. Shuman SK. A physician's guide to coordinating oral health and primary care. *Geriatrics*. 1990; 45: 47-57.

# Aquafresh

## \* FLEX \*



**PREVENTS GUM DAMAGE  
PROTECTS YOUR TEETH**

Marketed By

SmithKline Beecham Private Ltd.65C, Dharmapala Mawatha, Colombo 07

**NOW**

**AVAILABLE IN SRI LANKA**

**Helago Pharma - GmbH Germany**

*Introducing...*

**Dentipur<sup>®</sup>**

*The Complete program for modern denture care*

**Dentipur Rapid Cleansing tablets**

for a rapid and perfect cleansing  
of dentures and braces

**Dentipur fixative forte**

fixative powder for  
easy and stable fixing

**Dentipur cleansing-gel**

for rapid thorough cleansing  
and care by brushing

**Dentipur care-oil**

with camomile, cares in case  
of irritation of palate and gum

**Dentipur Top-dent denture brushes**

with long pliable bristles  
for gentle denture brushing

**Marketed by** HARCOURTS (PVT) LTD.,  
No.14 Station Road,  
Dehiwala.  
Tel: 074 200066, 075 524594

**Available at** HARCOURTS SUPER DRUGS STORE  
&  
Leading Pharmacies Islandwide



**CATAFLAM**

*Answer To* **ACUTE** *Dental Pain*

---

---


# ® CATAFLAM

diclofenac potassium

## FAST PAIN RELIEF

• 15 TO 30 MINUTES ONSET OF ANALGESIC ACTION •

Treatment of post-operative pain in a double-blind study of 97 patients following dental surgery during a four-hour treatment with Cataflam or placebo.<sup>(1)</sup>



## PROVEN EFFECTIVE FOR A WIDE RANGE OF PAINFUL AND INFLAMMATORY CONDITIONS

• EXCELLENT TO GOOD RESPONSES IN 93.7% OF CASES •

<p><b>R<sub>x</sub></b> CATAFLAM 50mg 1bd for 2 days.</p>	<p><b>R<sub>x</sub></b> CATAFLAM 50mg 2 stat followed by 1bd.</p>
<ul style="list-style-type: none"> <li>⇔ Severe Periapical pain</li> <li>⇔ Severe Post extraction pain.</li> <li>⇔ After draining of dental abscesses.</li> <li>⇔ Pericoronitis of 3rd molar.</li> </ul>	<ul style="list-style-type: none"> <li>⇔ For Pain Relief after Minor oral surgical procedures such as:                             <ul style="list-style-type: none"> <li>◆ Removal of impacted tooth - Canine, molar.</li> <li>◆ Apicectomy in root canal therapy.</li> <li>◆ Removal of buried roots/salivary calculi.</li> <li>◆ Alveolectomy &amp; Alveolplasty.</li> <li>◆ Removal of Dental cysts.</li> <li>◆ Fraenectomy/Gingivectomy.</li> </ul> </li> <li>⇔ After treatment of Mandibular &amp; Maxillary fractures</li> </ul>

**Presentation:** Diclofenac potassium: coated tablets of 25mg and 50mg; **Indications:** Short-term treatment in the following acute conditions: painful post-traumatic inflammatory states. Post-operative inflammation and pain. Painful and/or inflammatory conditions in gynaecology. Painful syndromes of the vertebral column. Non-articular rheumatism. As adjuvant in severe painful inflammatory infections of the ear, nose, throat. (Fever alone is not an indication). **Dosage:** Depending on the indication 75 - 150mg/day (dysmenorrhoea: up to 200mg). See full prescribing information. **Contra-indications:** Peptic ulcer, known hypersensitivity to the active substance, acetylsalicylic acid, or other prostaglandin synthetase-inhibiting drugs. Known sensitivity to sodium. **Precautions:** Symptoms/history of gastro-intestinal depletion from any cause. Patients on diuretics, anticoagulants, or antidiabetics. If in exceptional cases prolonged treatment proves necessary, periodic monitoring of liver function should be carried out and blood counts are recommended. See full prescribing information. **Adverse reactions:** Occasional: gastro-intestinal disorders, headache, dizziness, or vertigo, rash, elevation of SGOT, SGPT. Rare: peptic ulcer, gastro-intestinal bleeding, hepatitis, hypersensitivity reactions. In isolated cases: disturbances of sensation, erythema multiforme, purpura, abnormalities of renal function, blood dyscrasias. See full prescribing information. **Packs:** 50 x 10 tablets of 25mg and 50mg. Forensic classification: Prescription-Only-Medicine. Full prescribing information is available on request. From Novartis Pharma Sector A. Baur & Co. Ltd. No. 62 Jetawana Road Colombo 14, Tel: 074-616661 Fax: 336903.

CATA 6/SLU0799

(1) Data on file, Ciba-Geigy Limited, Basle, Switzerland (2) Folha Med(Br), 1986, 92: 53-63

**YOUR HEALTH IS OUR CONCERN  
PLACE YOUR TRUST IN US**

**Cephalosporins in the SPC range**

<b>Item Price</b>	<b>Supplier / Manufacturer</b>	<b>W/S Price</b>	<b>Retail</b>
1. Cefotaxime Inj 1g (GRAMOTAX)	Burk – India	82.25	92.55
2. Cefotaxime Inj 1g (KALFOXIM)	Kalbe Pharm – Indonesia	123.30	138.70
3. Cefiazidime Inj 1g	Medicuba –Cuba	334.10	375.85
4. Ceftriaxone Sodium Inj (BROADCED)	Kalbe Pharm – Indonesia	177.55	199.75
5. Cefuroxime Inj 750mg	Medochemi – Cyprus	115.10	129.50
6. Cefuroxime Inj 750mg	Lifepharm – Italy	131.55	148.00
7. Cephalexin Caps 250mg	M/C caryl – India	284.70	320.30
8. Cephalexin Syrup	Lyka – India	121.65	136.85
9. Cephalexin Tabs 125mg (CITACEPH-P)	Gitdl Pharma – India	404.35	454.90



No. 75, Sir Baron Jayathilake Mawatha,  
Colombo 01

Tel : 320356 – 9

Fax 447118

Website : [www.spc.lk](http://www.spc.lk)

E-mail : [pharmamd@slt.lk](mailto:pharmamd@slt.lk)

**DEDICATED  
TO  
QUALITY  
IN  
HEALTHCARE**

*We are dedicated to provide locally manufactured and imported healthcare products in Sri Lanka through a fully Sri Lankan owned company. We will achieve this by using the knowledge and skills of our employees who over the years have accumulated a vast store of experience and training in manufacturing and marketing quality healthcare products and transferring information to the medical professionals on the appropriate use of our products.*



**ASTRON LIMITED**

688, Galle Road, Ratmalana, Sri Lanka

**PFIZER** \*COMBANTRIN pyrantal embonate \*DIFLUCAN fluconazole  
\*FASIGYN tinidazole \*FELDENE piroxicam \*MINIPRESS prazosin HCl \*NORVASC  
amlodipine \*TERRAMYCIN IM oxytetracycline \*TROSYD tioconazole \*UNASYN  
sultamycillin \*VIBRAMYCIN doxycycline \*ZOLOFT sertraline \*VIAGRA sildenafil  
citrate

**ASTRON** ALLERMINE chlorpheniramine maleate \*ASTRIM co-trimoxazole  
\*ASTROCORT TOPICAL OINTMENT & Cream hydrocortisone \*AXCIL amoxycillin  
\*BECOSUL vitamin B complex with vit. B 12 \*BECOSULES high potency B complex  
+ vit C \*BEZINC vitamin B complex, vit C + zinc \*CLOXIL cloxacillin \*COPHATE  
codeine \*COREX/COREX D chlorpheniramine + codeine \*DIAMIDE chlorpropamide  
\*DUMASULES iron, vit. B complex with vit. C \*DUROL iron & B complex \*DUVIT  
BECO sugar coated vit. B complex \*EUGLIZIP glipizide \*EVIT vitamin E \*MINTERRA  
multivitamin \*MULTIFORTE multivitamin \*MULTI SCT multivitamin \*OVRON  
multivitamins & minerals \*OXIGARD betacarotene, vitamin C & E \*POLMYCIN  
TOPICAL OINTMENT oxytetracycline + polymycin B sulphate \*PREDLONE  
prednisolone \*PROTINEX vitamins, minerals & protein \*PYRANTIN pyrantel pamoate  
\*RAPISOL paracetamol \*SALMIN salbutamol \*TETRACIL tetracycline \*TETRACORT  
oxytetracycline + hydrocortisone \*ULCIBID cimetidine \*ZINCROX vitamins &  
minerals \*ACTION IQ supplementary food drink

## Burning Mouth Syndrome

S.P.A.G. Ariyawardana

Department of Oral Medicine and Periodontology, Faculty of Dental Sciences, University of Peradeniya

### **Introduction**

Burning Mouth Syndrome (BMS) has become a dilemma of diagnosis and treatment. Patients with burning mouth may consult not only dentists or a family doctor but also may seek help from physicians, oto-laryngologists, and dermatologists. Therefore, many patients receive varying types of treatment with unsuccessful results. BMS is a chronic oral pain disorder usually unaccompanied by mucosal lesions or other clinical signs.<sup>(1)</sup> This pain disorder can be regarded as a sensation perception abnormality affecting the oral mucosa and lips.<sup>(2)</sup>

Patients with BMS were labeled as "neurotic" because they do not show obvious physical causes. There is an increasing recognition of this disorder as a specific entity in the literature with emphasis on evaluation of the condition and the need for a long-term management strategy. The aim of this paper therefore, is to discuss the importance of medical and dental care which enable clinicians to manage the condition appropriately and with empathy.

### **Terminology**

The syndrome has been identified by many names. Most of these names are derived depending on the involved site of the oral mucosa. Glossodynia or glossalgia have been used to describe pain symptoms associated with the tongue whereas burning sensation of the tongue was termed as glossopyrosis. Likewise when other areas of the

mouth are affected the term stomatodynia or stomatopyrosis are used. However, all these can be described by the term Burning Mouth Syndrome regardless of the site affected.<sup>(3)</sup>

Burning sensation in the mouth can basically be divided into two main categories: a burning mouth with apparent clinical signs in the mouth or without any apparent clinical signs.<sup>(3,4)</sup> However, the term Burning Mouth Syndrome should be used to describe the burning sensation which is unaccompanied by clinical signs or idiopathic, which does not have identifiable aetiological factors.<sup>(3)</sup>

### **Epidemiological characteristics**

It is evident that the epidemiological features of idiopathic burning mouth syndrome are imprecise due to the variable terminology and range of conditions included as BMS. Although, there are many studies on demographic and clinical characteristics, only few population based studies have been reported.<sup>(4,5,6,7)</sup> Basker et al.<sup>(8)</sup> in a clinical study using patients from general dental practice, menopause and diabetic clinics in Birmingham and West Midlands reported a prevalence of 2.6% in those over the age of 20 years. Locker and Grushka<sup>(9)</sup> in a population-based study reported a prevalence of 4.5% using a sample of 1000 residents of Toronto, Canada. Tammiala-Solonen et al.<sup>(6)</sup> in another population based study in Finland showed a prevalence of 15%. However, half of this 15% had some clinically observable oral mucosal lesion/s attributable for the burning sensation. Therefore, it can be argued that the prevalence of idiopathic BMS must be less

than this figure. Furthermore, Savage<sup>(10)</sup> reported that about 10% of new referrals to his clinic included patients with BMS.

### *Clinical features*

BMS is more common in females with a female to male ratio of 7:1.<sup>(3,6,11,12)</sup> The majority of BMS patients are post-menopausal women<sup>(4,13)</sup> and middle aged women.<sup>(7)</sup> The occurrence of BMS under the age of 20 is very rare.<sup>(3)</sup> BMS generally encompasses the sensation of "burning" in one or more sites of the oral mucosa. However, it may be

accompanied with other complaints such as dryness in the mouth, altered or disturbed taste sensation<sup>(7)</sup>, dysphagia, sore throat, halitosis, cervico-facial muscular hypertonicity.<sup>(4,10)</sup> Symptoms are usually bilateral<sup>(11)</sup> affecting the tongue, lips, vermillion, anterior hard palate and occasionally circumoral skin.<sup>(2)</sup> Several authors<sup>(5,8,14,15)</sup> have reported on the prevalence of BMS by site (Table 1). Most patients complain of burning sensation as occurring at more than one site in the mouth. However, the commonest site of occurrence is the tip of the tongue.<sup>(2,11)</sup> Sites of complaints in order of frequency are shown in Table 2.

**Table 1.** Prevalence of BMS by site \*

Author	n	Percentage by site						
		Tongue	Lip	Buccal mucosa	Palate	Throat	Upper denture bearing area	Lower denture bearing area
Basker et al., (1978)	22	50	36	14	—	13	50	18
Main and Basker (1983)	37	67	34	18	—	05	68	25
Lamey and Lamb (1988)	150	78	38	04	—	08	45	36
Gorsky et al., (1991)	130	48	24	—	25	—	—	—

\* Percentages add up to more than 100 due to multiple site involvement.

**Table 2.** Sites of complaints in order of frequency

Order	Site
1	Tip of the tongue
2	Lateral borders of the tongue
3	Dorsum of the tongue
4	Lips
5	Buccal mucosa
6	Palate
7	Throat
8	Upper denture bearing area
9	Lower denture bearing area

Adapted from van der Ploeg et al.<sup>(16)</sup>

## Burning Mouth Syndrome

Burning mouth symptoms may take several months to evolve in a “waxing and waning” pattern with some patients showing complete remission and reappearance.<sup>(2)</sup> Symptoms are variable among patients and within an individual the severity varies from time to time.<sup>(10)</sup> Lamey and Lewis<sup>(11)</sup> have categorized the symptoms of BMS into three types. In type I, the patient wakes up with no symptoms, and burning sensation begins to appear gradually and the severity increases as the day goes on. In type II, burning is present on awakening and persists throughout the day whereas in type III, there may be symptom free days. This classification may be useful in assessing the progress in which type I shows the best prognosis.

### *Aetiology*

The exact aetiology is yet to be determined. However, many local and systemic factors have been identified as causative factors for burning sensation. van der Waal<sup>(3)</sup> has divided the possible factors into 4 main categories namely, local, systemic, neurological and psychogenic.

### *Local factors*

Local factors include mucosal lesions, prosthetic appliances, dental treatment, metal allergy, food allergy, smoking and use of alcohol. Many mucosal lesions and conditions may produce BMS like symptoms. Among them candidal infection, geographic tongue, oral lichen planus (mainly erosive type), oral ulceration and oral submucous fibrosis play a significant role.<sup>(3)</sup> Lamey and Lamb<sup>(15)</sup> have reported a prevalence of candida species in 40% of the patients with burning mouth symptoms. However, only one in seven of these patients having candida in their mouths had relief after anti candidal treatment. Geographic tongue is often asymptomatic and therefore most of the patients are not aware of its presence in the mouth. However, some may develop burning symptoms.

Gorsky et al.<sup>(17)</sup> reported that 15% of their 98 patients had geographic tongues. Among many morphological types of oral lichen planus the erosive or atrophic forms are mainly responsible for burning mouth symptoms.<sup>(18)</sup> Dentures have been regarded as one of the aetiological factors in oral burning.<sup>(3,15)</sup> Burning sensation in these patients is considered to be attributable for faulty dentures (articulation and stability etc.)<sup>(14)</sup> and allergy to polymethyl methacrylate.<sup>(15)</sup> However, some authors questioned the possible correlation between burning mouth symptoms and faulty dentures.<sup>(17,19)</sup> Some patients may demand for many kind of dental treatments as a remedy for their burning symptoms.<sup>(20)</sup> In a retrospective study Mock et al.<sup>(21)</sup> had shown that symptoms of atypical facial pain can either persist or aggravate after dental treatment such as extraction, root canal treatment, in about 75% of patients. Oral galvanism, a phenomenon of currents resulting from an electrical reaction between metal dental restorations has also been identified as a causative factor for oral burning.<sup>(3)</sup> However, controlled studies on patients with BMS symptoms and those without, have shown similar currents in both groups.<sup>(22)</sup> Contact allergy to dental restorative materials has been suggested as an aetiological factor for burning mouth symptoms.<sup>(1)</sup> However, supportive evidence for this phenomenon is lacking.<sup>(15,23)</sup> A correlation between food allergy and burning symptoms has been mentioned in the literature. Sensitivity to some food-related products such as sorbic acid, propylene glycol, benzoic acid and cinnamon was discovered on patch testing. Dietary advice for patients to abstain from those materials led to the disappearance of symptoms.<sup>(15)</sup> Dysfunction or parafunction have been thought to have an aetiological value.<sup>(1,15,24)</sup> Individuals who grind teeth or clench can thrust their tongue against teeth leading to burning sensation especially in the lateral borders of the tongue. Dryness of the mouth or reduced saliva is a frequent complaint in patients with BMS.<sup>(2,5,25)</sup>

### ***Systemic factors***

Although, many systemic factors have been shown to be associated with BMS like symptoms, most of the investigators have not detected any consistent specific medical condition that is causally linked to BMS. Deficiency status of iron and vitamins including vitamin B1, B2, B6 and B 12 can lead to mucosal burning complaints.<sup>(26)</sup> Iron deficiency anaemia has been considered as an important aetiological factor in causing burning symptoms in the mouth.<sup>(7,15)</sup> However, recent studies have shown a non significant relationship of such deficiencies with BMS.<sup>(4,26)</sup> Diabetes mellitus has also been recognized as a causative factor for burning mouth symptoms.<sup>(15)</sup> Gibson et al.<sup>(27)</sup> have investigated 43 previously undiagnosed non-insulin dependent diabetes mellitus patients and showed that 16 of them had burning mouth symptoms which disappeared after therapy for diabetes. Burning mouth symptoms may be attributed to metabolic alteration and oral candidal infection in diabetic patients.<sup>(1)</sup> Grushka<sup>(4)</sup> has suggested an immunologic basis for BMS. He has shown that 58% of BMS patients are associated with some immunologic abnormality. Reflux oesophagitis was also found as a factor in causing BMS.<sup>(15)</sup> However, no further studies have been conducted in this regard. Many drugs can cause side effects in the mouth. Some of them may directly or indirectly cause burning mouth symptoms.<sup>(28)</sup>

### ***Neural mechanisms***

It is likely that the BMS is a reflection of a neuropathic condition involving either central or peripheral mechanism or both.<sup>(20, 25)</sup> Nerve injury or dysfunction due to oral, facial and systemic trauma or certain medical conditions may lead to such changes in the central nervous system.<sup>(20,29)</sup> Lack of significant link with known diseases and no apparent abnormalities in the oral mucosa may

support the above assumption. Burning pain is one of the features of several chronic pain conditions associated with nerve damage.<sup>(25)</sup> These changes in the central nervous system are considered to be due to neuroplasticity in the central nociceptive pathways. Damage or inflammation of the peripheral tissues or nerves can produce long lasting neuroplastic changes in the central nervous system. This central sensitization may lead to hyperalgesia, spontaneous pain and pain referral.<sup>(29)</sup> Therefore, it can be assumed that BMS is a central nervous system abnormality. The peripheral nerve alteration which leads to tonic input to the CNS can be responsible for burning sensation. This can occur in inflammatory conditions or nerve injuries. However, this mechanism in long term burning is doubtful.<sup>(25)</sup> Furthermore, local anaesthesia or topical analgesic solutions are ineffective in alleviating burning mouth symptoms.<sup>(25, 30)</sup>

### ***Psychological factors***

Psychiatric morbidity has frequently been cited as a causally related factor in BMS.<sup>(14,16,31-36)</sup> However, the cause and effect relationship is not very clear. Browning et al.<sup>(33)</sup> found that significantly a higher proportion of patients with a burning mouth (44%) had an associated psychiatric disorder compared to the control group (16%). Depression was reported more frequently in the burning mouth syndrome group. Rojo et al.<sup>(36)</sup> reported psychiatric involvement in 51% of patients with BMS. Depression was the commonest finding with BMS (31%) and anxiety was much less common (11%). On the contrary, Lamey and Lamb<sup>(34)</sup> claimed that anxiety to be more relevant than depression using Hospital Anxiety and Depression scale (HAD) to patients with BMS. Lamb et al.<sup>(37)</sup> had reported psychiatric morbidity in more than 50% of patients who suffer from BMS. A higher incidence was found in type II than in type I BMS. In a clinical study Humpf et al.<sup>(32)</sup> identified that 92% of patients with dysaesthesia were psychotic.

## Burning Mouth Syndrome

Twelve patients out of 34 who suffered from atypical facial pain were found to be psychotic and 7 out of 10 patients with BMS were suffering from pathological personality disorder. An underlying psychological problem, though the exact nature was uncertain has been found in many cases of chronic orofacial pain including orofacial pain and oral dysaesthesia.<sup>(21,32,38)</sup> Schoenberg<sup>(31)</sup> stated that the burning mouth is a symptom of depression resulting from psychological stress. The specific psychological stress could be a real or threatened loss of a loved person, a related object or a bodily function. Cancerphobia also has been found to be a significant factor. Lamey and Lewis<sup>(11)</sup> stated that approximately 20% of BMS patients were cancerphobic. In most of the studies carried out in the past, attempts have been made to ascertain the presence of psychiatric illness in association with BMS. However, they do not provide a causal relationship with BMS. Nevertheless, it is important to evaluate psychiatric involvement with regard to successful management of BMS. Indeed the psychiatric disorder could be a result of chronic pain or BMS rather than the opposite way.

### *Menopause and BMS*

It is evident that BMS is more common in postmenopausal women.<sup>(3,8,13)</sup> Menopause (climacteric) is a natural process of cessation of menstruation which eventually occurs in all females. Climacteric period in which substantial hormonal changes occur is characterized by physical and emotional changes. Among them are vasomotor changes such as hot flushes, profuse perspiration, palpitations and psychological symptoms such as depression, irritability, tiredness, nervousness and other complaints such as headaches, insomnia and vaginal discomfort.<sup>(39)</sup> Oral discomfort with burning sensation is also a common complaint. Wardrop et al.<sup>(13)</sup> reported that the prevalence of depression, nervousness,

apprehension and headaches were significantly higher in postmenopausal women who experienced oral discomfort than who did not. Basker et al.<sup>(8)</sup> reported oral discomfort in 26% of postmenopausal women. Out of this, 43% complained of only burning sensation, 27% had strange taste and 30% a combination of both. These figures are contrastingly higher than the prevalence in the general population<sup>(8)</sup> and premenopausal women.<sup>(13)</sup> Furthermore, Grushka<sup>(4)</sup> has shown that post-menopausal women experience burning mouth at about the time of menopause and symptoms are more severe than in the female control subjects. It has been claimed that hormonal changes that occur in menopause are responsible for the discomfort in the mouth.<sup>3</sup> Wordrop et al.<sup>(13)</sup> argued that the success of estrogen replacement therapy (ERT) in BMS is due to alleviation of psychological distress. Forabosco et al.<sup>(40)</sup> argued that the success of ERT in relieving BMS is attributed to the presence of estrogen receptors in the oral mucosa. However, some studies have not demonstrated a dramatic improvement of oral symptoms with ERT.<sup>(4,8,41)</sup> Although, it is difficult to explain the exact association with menopause, it appears that there may be a link, as yet unclear with the psychological changes that occur at menopause.

### *Assessment*

It is important to assess the patient's condition properly prior to any treatment. Most of the patients probably would have consulted numerous specialists, all of whom would have proclaimed that the oral mucosa is healthy. Furthermore, these patients may claim that they have been treated with many medications with unsuccessful results. Some of the patients may believe that their problem is attributed to oral cancer or any other sinister disease. It is of utmost importance to be sympathetic towards the patient's problem. In addition to the pain history, medical and psychosocial evaluations are mandatory.<sup>(2)</sup> In all

circumstances, regardless of the extent and severity of the symptoms, a meticulous inspection of the oral cavity should be carried out. All mucosal changes should be thoroughly inspected. In addition to the examination of the mucosa, any signs of dry mouth, salivary consistency and flow should be determined.<sup>(3)</sup> If any positive finding is present, the appropriate tests including salivary analysis, allergy tests, haematological and biochemical investigations should be carried out to confirm the diagnosis. The need for specific laboratory tests should be assessed individually. Haematological investigations should include full blood count, differential count and blood picture. Other biochemical tests should include, serum iron, total iron-binding capacity, serum folate, serum B<sub>12</sub>, B<sub>1</sub>, B<sub>2</sub> and B<sub>6</sub> levels. In addition, the fasting blood sugar level also should be carried out to exclude diabetes in suspected cases. Furthermore, it is necessary to obtain a second opinion from a psychiatrist, haematologist, rheumatologist, allergist or physician wherever appropriate. When the organic cause for burning symptoms cannot be found the diagnosis of idiopathic BMS should be established. In other words the diagnosis of BMS is established by elimination of possible causes for the burning mouth symptoms.

### *Treatment*

If an underlying cause for the burning mouth symptoms is found, the treatment should be directed towards the elimination of such a cause or causes.<sup>(5,24,42)</sup> If several causes are identified they should be addressed simultaneously.<sup>(42)</sup> However, treatment based on any of those suspected aetiologic factors is often ineffective in idiopathic BMS.<sup>(2,25)</sup> The treatment of idiopathic BMS is generally difficult. A long-term strategic approach should be used. Psychiatric referral may be necessary in some patients and a joint clinical management with a psychiatrist may be beneficial in successful management.<sup>(2)</sup> Self-regulation strategies such as

diversion, distraction and thought stopping should always be discussed with the patient. After being properly informed about the various aspects of BMS, most patients do not insist on any type of drug treatment.<sup>(16)</sup> Elimination of cancerphobia is extremely valuable for those who suffer from it.<sup>(3)</sup> In any case the patient should be offered a follow up appointment in about 3-6 months time in order to evaluate the success of the management. However, in spite of proper explanation and reassurance some patients may demand further investigations and treatment.

### *Drug treatment*

In the absence of identifiable causes pharmacological therapy has been suggested for the treatment of BMS. Among them antidepressants, benzodiazepines play a significant role.<sup>(2,24)</sup> Antidepressants such as amitriptyline or imipramine are useful for chronic pain disorders including BMS.<sup>(5)</sup> Their effect is mainly analgesic independent of antidepressant effects.<sup>(43)</sup> These drugs function by inhibiting the re-uptake of serotonin and norepinephrine.<sup>(1)</sup> As with chronic pain, improvement can be achieved in some patients with a low dose of 10-20 mg as a single dose at night. These medications should be taken regularly over some weeks before a change can be expected. Newer serotonin specific re-uptake inhibitors (SSRI) such as fluoxetine and paroxetine are also available. However, the efficacy of these agents in BMS or chronic orofacial pain is doubtful.<sup>(2)</sup> Nevertheless, they can be certainly beneficial for depressed patients with BMS.<sup>(1)</sup>

Anxiolytics also have been tried in some studies and the administration of chlordiazepoxide has some beneficial effects. Gorsky et al.<sup>(5)</sup> in a clinical study of 78 patients have shown marked improvement of symptoms in 49% of patients with administration of chlordiazepoxide and a 66% improvement in a small sample of 6 patients with

## Burning Mouth Syndrome

the administration of diazepam. However, clinically observable benefits were not found from benzodiazepines in the treatment of BMS.<sup>2</sup> A new modality of treatment was reported in the recent past using a neuropeptide "capsaicin".<sup>(44)</sup> Capsaicin, a neuropeptide extracted from hot pepper, has been shown to reduce and eliminate the accumulation of substance P. However, the author concludes that further controlled studies are needed to clarify the efficacy on neuropathic pain. The use of viscous solution of 2% lidocaine hydrochloride in carboxymethyl cellulose sodium also had been used as a symptomatic relief.<sup>(3)</sup> It has been shown that oral rinse of benzydamine hydrochloride have no significant efficacy in comparison with placebo solution.<sup>(30)</sup>

### References

1. Lang E, Niv D. Burning mouth syndrome. *Pain Digest* 1998; 8: 153-157.
2. Hay K D, Large R G. Burning mouth syndrome and oral dysaesthesia. *New Ethicals* 1995; July: 57-65.
3. van der Waal I. *The burning mouth syndrome*. Copenhagen. Munksgard 1990.
4. Grushka M. Clinical features of burning mouth syndrome. *Oral Surg Oral Med Oral Pathol* 1987; 63: 30-36.
5. Gorsky M, Silverman S, Chinn H. Clinical characteristics and management outcome in the burning mouth syndrome – An open study of 130 patients. *Oral Surg Oral Med Oral Pathol* 1991; 72: 192-195.
6. Tammiala- Salonen T, Hidenkori T, Parvinen T. Burning mouth in a Finnish adult population. *Comm. Dent. Oral Epidemiol* 1993; 21: 67-71.
7. Bergdahl J, Anneroth G, Anneroth I. Clinical study of patients with burning mouth. *Scand J Dent. Res* 1994; 102: 299- 305.
8. Basker RM, Sturdee DW, Davenport JC, Patients with burning mouths – A clinical investigation of causative factors, including the climacteric and diabetes. *Br Dent J* 1978; 145: 9-16.
9. Locker D, Grushka M. Prevalence of Oral and Facial pain and discomfort: preliminary results of Mail survey. *Com Dent Oral Epidemiol* 1987; 15: 169-172.
10. Savage N W. Burning mouth syndrome: Patient management. *Aust Dent J* 1996; 41(6): 263-266.
11. Lamey P J, Lewis M. A. O. Burning mouth syndrome. *Br Dent J* 1989; 167: 297-200.
12. Lamey P.J. Burning mouth syndrome: Approach to successful management. *Dent Update* 1998; Sept: 298- 300.
13. Wardrop R W, Hailes J, Burger H, Reade P C. Oraldyscomfort at menopause. *Oral Surg Oral Med Oral Pathol* 1989; 67: 535-540.
14. van der Ploeg H M, van der Wall N, Eijkman M. A J, van der Waal I. Psychological aspects of patients with burning mouth syndrome. *Oral Surg Oral Med Oral Pathol* 1987; 63: 664-668.
15. Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. *Br Med J* 1988; 296: 1243-1246.
16. Gorsky M, Silverman S, Chinn H. Burning mouth syndrome – a review of 98 cases. *J Oral Med* 1987;42: 7-9.
17. Regezzi JA, Scubba JJ. *Oral Pathology: Clinical and pathologic correlations*. 3 rd edition. Philadelphia. Saunders, 1999; 101-106.
18. Main DMG, Basker R M. Patients complaining of a burning mouth. Further experience in clinical assessment. *Br Dent. J* 1983; 154: 206-211.
19. Nater JP, Groenman NA, Wakkens- Garristsen B.G, Timmer L H. Etiological factors in denture sore mouth syndrome. *J Prost Dent* 1978; 40: 367-373.
20. Cibrika RM, Nelson ST, Lefebvre CA. Burning mouth syndrome: A review of etiologies. *J Prost Dent* 1997; 78(1): 93-97.
21. Mock D, Frydman W, Gordon AS. Atypical facial pain: A retrospective study. *Oral Surg Oral Med Oral Pathol* 1985; 59: 472-474.
22. Johansson B, Stenman E, Berman M. Clinical registration of charge transfer between dental metallic materials in patients with disorders and

- or discomforts, allergy caused by corrosion. *Scand J Dent Res* 1986; 94: 357-363.
23. Hammaren M, Hugoson A. Clinical psychiatric assessment of patients with burning mouth syndrome resisting oral treatment. *Swed Dent J* 1989; 13: 77-88.
  24. Yontchev E, Meding B, Hedegard B. Contact allergy to dental materials in patients with orofacial complaints. *J Oral Rehab* 1986; 13: 183-190.
  25. Tourne LPM, Friction JR. Burning mouth syndrome: critical review and proposed clinical management. *Oral Surg Oral Med Oral Pathol* 1992; 74:158-167.
  26. Ship J A, Grushka M, Lipton J A, Mott A E, Barry J S, Dionne R A. Burning mouth syndrome: An update. *JADA* 1995; 126: 843- 853.
  27. Lamey PJ, Hammond A, Allam BF, McIntosh W.B. Vitamin status of patients with burning mouth syndrome and the response to replacement therapy. *Br Dent J* 1986; 160: 81-84.
  28. Gibson J, Lamey PJ, Lewis M. Oral Manifestations of previously undiagnosed NIDDM. *J Oral Pathol Med* 1990; 19: 284-287.
  29. Scully C, Cawson RA. Medical problems in dentistry. 4<sup>th</sup> edition. Oxford. Wright 1998: 506-528.
  30. Urban M O, Febhart G F. Central mechanisms in pain. *Med Clin Nrh Am* 1999; 83(3) 585-595.
  31. Sardella A, Uglietti D, Demarosi F, Lodi G, Bez C, Carrassi A. Benzydamine hydrochloride oral rinse in management of burning mouth syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1999; 88: 683-686.
  32. Schoenberg B. Psychogenic aspects of the burning mouth. *N.Y Stat Dent J* 1968; 33(8): 249-255.
  33. Hampf G, Vikkula J, Ylipaavalniemi P, Aalberg V. Psychiatric disorders in orofacial dysaesthesia. *Int J Oral Maxfac Surg* 1987; 16: 402-407.
  34. Browning S, Hislop S, Scully C, Shirlaw P. The association between burning mouth syndrome and psychological disorders. *Oral Surg Oral Med Oral Pathol* 1987; 64: 171-174.
  35. Lamey P J, Lamb A B. The usefulness of the HAD scale in assessing anxiety and depression in patients with burning mouth syndrome. *Oral Surg Oral Med Oral Pathol* 1989; 67: 390-392.
  36. Rojo L, Silvestre FJ, Bagan JV, Vicente TD. Psychiatric morbidity in burning mouth syndrome – psychiatric interviews versus depression and anxiety scales. *Oral Surg Oral Med. Oral Pathol* 1993; 75: 308- 311.
  37. Lamb A B, Lamey P J, Reeve P E. Burning mouth syndrome – Psychological aspects. *Br Dent J* 1988; 165: 256- 260.
  38. Feinman C, Harris M. Psychogenic facial pain. *Br Dent J* 1984; 156: 165-168.
  39. Drury P.L. Endocrinology. In: Kumar P, Clark M (editors) *Clinical medicine: A textbook for medical students and doctors*. 3<sup>rd</sup> edition. London. Bailliere Tindall. 1994: 785-786.
  40. Forabosco A, Criscuolo M, Coucos G, Uceli E, Weinstein R, Botticelli A, Voipe A. Efficiency of hormonal replacement therapy in post menopausal women with oral discomfort *Oral Surg Oral Med Oral Pathol* 1992; 73: 570-574.
  41. Ferguson M M, Carter J, Boyle P, Hart D. M, Lindsay R. Oral complaints related to climacteric symptoms in oophorectomised women. *J Roy Soc Med* 1981; 74: 492-498.
  42. Brightman VJ. Oral symptoms without apparent physical abnormality – Atypical facial pain, glossodynia and burning mouth syndrome, subjective xerostomia and idiopathic dysgeusia. In: Lynch M A., Brightman V J., Greenburg M S. (editors) *Burket's oral medicine*. 9<sup>th</sup> edition. Lippincott. Philadelphia 1994; 396-398.
  43. Sharav Y, Singer E, Schmidt E, Dionne R A, Dubner R. The analgesic effect of amitriptyline on chronic facial pain. *Pain* 1987; 31: 199-209.
  44. Epstein J B, Marcoe J H. Topical application of capsaicin for treatment of oral neuropathic pain and trigeminal neuralgia. *Oral Surg Oral Med Oral Pathol*. 1994; 77:135-140.

*FOR QUALITY*

*DENTAL MATERIAL, INSTRUMENTS*

*&*

*ARTIFICIAL TEETH*

**CHIVKONZER & COMPANY**

**174, MEZZANINE FLOOR  
PANCHIKAWATTE ROAD**

**P.O. BO 987  
COLOMBO 10**

**TEL : 433249**

**FAX : 438268**



**Gamma Pharmaceuticals (Pvt) Ltd**  
**476, Union Place,**  
**Colombo 02.**

Tel : 696071, 698078, 698054

Fax : 696427

**LOLC**

*Creating Lasting Value*

**Lanka ORIX Leasing Company Limited**

**Head Office :** 100/1, Sri Jayewardenepura Mw, Rajagiriya  
Tele: 865604-10, 868665-6, 867637-50, Fax : 868648

**Branch Office:** 129 1/3, D.S. Senanayake Veediya, Kandy  
Tele: 08-233578/9, 224436/7, 233571, Fax: 08-233579

276, Anagarika Dharmapala Mw, Matara  
Tele: 041 – 27300 – 3, Fax: 055 – 30900

2, Riverside Road, Badulla  
Tele: 055-30899/9, Fax: 055-30900

252 1/1, Colombo Road, Ratnapura  
Tele/ Fax : 045-30054-6

3125, Stage 111, Dahaiyyagama Junction,  
Anuradhapura  
Tele: 025-24921-3

Regal Building, 60/2, Chillaw Road  
Kochchikade  
Tele/ Fax : 031-76121-3

## **Dental Services Company**

141, Vauxhall Street, Colombo 02 Tel ; 335175 , 304185 Fax : 304186 Hot Line : 421969

# **HI - TECH DENTAL LABORATORY**

The Pioneer Commercial Porcelain Laboratory

For All Your Dental Laboratory Work

- \* *Porcelain Bridge Work*
- \* *Maryland Bridges*
- \* *Chrome Cobalt Full and Partial Dentures*
- \* *Overdenture abutments for Dental Implants*

### **SOLE AGENT**

\* *T.P. ORTHODONTICS INC. U.S.A.*  
Full line of orthodontic appliances

\* *INNOVA CORP - CANADA*  
The endopore dental implant system  
Tel: 335175, 304185  
Fax: 304186, 421969

## RESEARCH ARTICLE

### Recurrence of disease and survival of oral cancer patients treated at the Faculty of Dental Sciences, Peradeniya

N.A. de S. Amaratunga and J.U. Weerasinghe

Department of Oral Surgery, Faculty of Dental Sciences, University of Peradeniya

#### Abstract

**Introduction:** Pattern of local spread, metastasis and recurrence of oral cancer may be different in different societies where different aetiological factors could be in operation. Survival rate of patients would depend on these factors. **Material and method:** Hospital records of thirty three live patients and fifty dead patients were studied to determine personal details, site of the lesion, method of treatment, recurrence and period of survival after initial treatment. **Results:** Overall recurrence rate within three years was 50.6% and in 25.3% of these cases the recurrence had occurred during the first year after treatment. Three year survival rate was 69.8% and the five year survival rate was 39.7% and in both parameters the patients who had local resection only and those who had surgery and radiotherapy recorded higher survival rates than other groups. **Discussion:** Recurrence rate and three year survival rate compares favourably with the findings of previous studies. Five year survival rate appears to be poor in comparison. More comprehensive treatment modalities and predictive investigations may have to be employed for better results.

**Key words:** oral cancer, recurrence, survival rate, treatment protocol, neck nodes

#### Introduction

Natural behaviour with regard to local spread, metastasis and recurrence of oral cancer could be different when the aetiological factors are different. Aetiological factors in operation may differ from country to country, and society to society. Tobacco habits which is the main cause may be different in different countries. Some may smoke it in various forms, some may chew it with different other substances, others may use it as a snuff. Behaviour pattern of oral cancer could be different in these different societies. Thus it may be necessary to determine the survival rate of oral cancer patients in Sri Lanka. This retrospective study is an attempt to do this using patients treated at the Oral Surgery Department, Faculty of Dental Sciences, Peradeniya.

#### Material and Method

One hundred and three patients who had been treated for oral cancer at the Department of Oral Surgery, Faculty of Dental Sciences, University of Peradeniya, prior to August 1994 were recalled in the month of August 1999. The letters sent to these patients were addressed to their next of kin who were requested to inform us if the patient was not alive giving us the date the patient died. They were also requested to let us know whether the patient had been treated elsewhere after the last date he/she attended our unit. Thirty Five patients attended our clinics while in the case of 54 the next of kin replied giving the date on which the patient had died. Thus, there was a total compliance rate of 89.3%. The hospital records of these eighty six patients were perused to

determine the personal details, site of the lesion, method of treatment and recurrence and its management, and period of survival after initial treatment. Four subjects were rejected as the information could not be accurately determined due to incomplete records. Thirty three of the patients who attended the clinic and whose records were satisfactory were included in the study and were further examined clinically to determine whether there was any recurrence and/or metastasis and also whether they had been treated elsewhere after the last date he/she had attended our unit. The final study group consisted of thirty three live patients and 50 patients who had died prior to August 1999. It was assumed that these 50 patients had died due to the oral cancer and its direct complications. In the statistical analysis the

chi-square test was employed to determine the significance of difference between proportions.

*Results*

Age at time of initial diagnosis and sex distribution is shown in Table 1. A large majority (74.7%) of patients were in the age groups 50-59 and 60-69. Similarly there was a preponderance of males (84.3%).

Distribution of patients according to the site of the cancer is given in Table 2. The commonest site was the buccal mucosa and the next common site was the commissure and lip area. Cancer was found to be more common in the floor of the month than in the tongue. Palate was the least common site.

**Table 1:** Age (at initial diagnosis) and sex distribution of the study group

Age Group	Live		Dead		Total
	Male	Female	Male	Female	
40-49	04	03	06	01	14 (16.9%)
50-59	11	02	14	05	32 (38.6%)
60-69	10	0	19	01	30 (36.1%)
70-79	03	0	03	0	06 (7.2%)
80-89	0	0	0	01	01 (1.2%)
Total	28 (33.7%)	05 (6.1%)	42 (50.6%)	8 (9.6%)	83 (100%)

**Table 2:** Distribution according to site of primary lesion

Site	Male (%)	Female (%)	Total (%)
Buccal	23 (27.7%)	5 (6.0%)	28 (33.7%)
Commisure & Lip	20 (24.1%)	3 (3.6%)	23 (27.7%)
Tongue	10 (12.0%)	2 (2.5%)	12 (14.5%)
Floor	11 (13.3 %)	3 (3.6%)	14 (16.9%)
Palate	06 (7.2%)	0	06 (7.2%)
Total	70 (84.3%)	13 (15.7%)	83 (100%)

### Recurrence of disease and survival of oral cancer patients

Methods employed in the treatment of these patients are given in Table 3. A combination of surgery and radio therapy was the most frequent (45.8%) method of treatment. Surgery involving neck dissection had been done in 18 (21.7%) patients, local resection only in 14 (16.9%) and radical resection without neck dissection in 13 (15.6%). In a total of 42 (50.6%) patients there had been recurrence of the disease which needed further treatment.

Table 4 shows the recurrence of disease after initial treatment. Twenty one (25.3%) of these patients had the recurrence during the first year after treatment, 9 (10.8%) during the second year and 12 (14.5%) during the third year. The commonest site of recurrence was the primary site of the lesion. A total of 24 (28.9%) patients which

amounts to more than half (57%) had a recurrence at the primary site. Recurrence in the cervical lymph nodes was detected in 17 (20.5%). Distant metastasis was rare with only one patient being detected with it.

Crude three year survival rate in relation to the method of treatment is shown in Table 5. Patients numbering 14 who had a local resection only had a survival rate of 100%. Of the rest of the patients those who had radical surgery and radio therapy had recorded a three year survival rate of 68.4% while those who had surgery and neck dissection had recorded a survival rate of 61.1% and those who had radical resection without neck dissection recorded a survival rate of 53.8%. The difference between these proportions was statistically significant ( $p < 0.01$ ). The overall crude three year survival rate was 69.8%.

**Table 3:** Treatment method

Local Resection	Radical Resection	Resection & Neck Dissection	Surgery & Radiotherapy	Total
14 (16.9%)	13 (15.6%)	18 (21.7%)	38 (45.8%)	83 (100%)

**Table 4 :** Recurrence of disease after initial treatment

Site of Recurrence	Within First Year	Within Second Year	Within Third Year	Total
Primary	12 (14.4%)	5 (6.0%)	7 (8.5%)	24 (28.9%)
Neck nodes	09 (10.9%)	4 (4.8%)	4 (4.8%)	17 (20.5%)
Distant	0	0	01 (1.2%)	01 (1.2%)
Total	21 (25.3%)	9 (10.8%)	12 (14.5%)	42 (50.6%)

**Table 5 :** Three Year survival rate in relation to method of treatment

Method of Treatment	Three years after initial treatment			Survival Rate
	Alive	Dead	Total	
Local	14	0	14	100%
Radical	7	6	13	53.8%
Neck Diss.	11	7	18	61.1%
Surgery+RT	26	12	38	68.4%
Total	58	25	83	69.8%

RT – Radio Therapy

Table 6 presents the crude five year survival rate in relation to the method of treatment. The overall five year survival rate was 39.7%. The five year survival rate in patients who had local resection was 85.7%, that in patients who had radical resection was 30.7%, in patients who had neck dissections it was 16.6% and in those who had a combination of surgery and radiotherapy it was 36.8%. The difference between these proportions was statistically significant ( $p < 0.01$ ). Three year

survival rate in relation to age and sex is presented in Table 7. The overall three year survival rate for males was 70% while it was 61.5% for females, the difference being statistically significant ( $p < 0.01$ ). There was no significant difference in the overall three year survival rate for the age groups 40-49, 50-59, and 60-69 ( $p < 0.01$ ). Within each gender however there were statistically significant differences in the survival rate between age groups.

**Table 6 :** Five year survival rate in relation to method of treatment

Method of Treatment	Five years after initial treatment			Survival Rate %
	Alive	Dead	Total	
Local	12	02	14	85.7
Radical	04	09	13	30.7
Neck Diss.	03	15	18	16.6
Surgery+RT	14	24	38	36.8
Total	33	50	83	39.7

RT – Radio Therapy

**Table 7 :** Three year survival rate in relation to age and sex

Age Group	Male			Female			Total		
	Alive	Dead	SR %	Alive	Dead	SR %	Alive	Dead	SR %
40-49	7	3	70	3	1	75	10	4	71.4
50-59	19	6	76	3	4	42.8	24	10	70.5
60-69	21	8	72.4	1	0	100	20	8	71.4
70-79	3	3	50	0	0		3	3	50
80-89	0	0		1	0	100	1	0	100
Total	50	20	70	8	5	61.5	58	25	69.8

SR – Survival Rate

### Discussion

This series of patients was homogeneous in the sense that two surgeons were responsible for the surgery and two oncologists were responsible for

radiotherapy. However this was a retrospective study that relied heavily on hospital records which could be a source of error. One major draw back was the fact that the oral cancers had not been satisfactorily staged according to an acceptable

## Recurrence of disease and survival of oral cancer patients

method. Further details of radiotherapy was not available and there was no way of controlling this variable factor. Yet as only two surgeons and two oncologists were involved in the treatment it was not difficult to ascertain that treatment regimens were based on acceptable protocols. Due to the above constraints the investigation into recurrence and survival could not be related to the stage of malignancy but was related to less important criteria such as method of treatment, age and sex. However the results of the study are useful as they give a good idea of recurrence rates and survival rates of oral cancer patients in Sri Lanka and when these are related to treatment protocols useful information could be gleaned from the data so analyzed.

The overall recurrence rate of oral cancer was found to be 50.6% which compares favourably with figures reported in other studies.<sup>(1,2,3)</sup> Commonest site of recurrence was the primary site and in half of the patients the recurrence was observed during the first year. This could mean inadequate marginal resection. Invaded resection margins were found to be a factor in recurrence in previous studies<sup>(4)</sup>. The finding that most of the recurrence occurred during the first two years postoperatively is in agreement with that of other studies<sup>(3)</sup>. Next common site for recurrence was the cervical lymph nodes. Whether this finding supports the view that neck nodes should be treated irrespective of whether or not they are clinically affected could not be clearly ascertained due to lack of proper records. However a nodal recurrence rate of 20.5% could be considered as satisfactory when compared with the 32% reported by Pradier et al.<sup>(3)</sup> who recommend nodal clearance for early stage tumours. In this series neck nodes had been treated only when they were clinically affected.

The overall three year survival rate of 69.8% compares favourably with figures reported in other

studies.<sup>(5,4,1)</sup> Local resection without neck dissection and/or radiotherapy had given the best survival rate of 100%. This finding cannot be taken at its face value. It is probable that these patients had Stage I or II tumours which required only a local resection. The five year survival rate (85.7%) too was satisfactory for these patients. Thus the question arises whether the early stage tumours in Sri Lankan patients need to be treated with neck dissection and also radiotherapy. If they are subjected to such intensive treatment perhaps their survival would improve further. This point of view is supported by other authors.<sup>(6,5)</sup> Raybaud et al.<sup>(7)</sup> say that it has been observed that tumours of the same grade or stage do not necessarily behave similarly; small tumours may show a high recurrence and mortality rate whereas larger tumours may fail to recur. Such behaviour is not commonly observed in Sri Lankan patients. However it may be necessary to identify more reliable prognostic indicators and plan treatment accordingly. For instance radio-resistance could be predicted using p53 protein accumulation<sup>(8)</sup> and tumour DNA content.<sup>(7)</sup> Such expensive investigations may not always be possible in Sri Lanka but what could be appropriate is the use of multifactorial histologic grading system for malignancy<sup>(9,10)</sup> in combination with clinical TNM staging system in order to acquire a more accurate basis for prognosis prediction and choice of treatment.<sup>(11)</sup>

Apart from the group who had local resection only, the highest three year and also five year survival rates were recorded by the group who had a combination of radical surgery and radiotherapy. Similar findings have been reported by other authors.<sup>(5,1)</sup> Patients who had neck dissection without radiotherapy had a better three year survival rate (61.1%) compared to those who had only radical resection (53.8%) ( $p < 0.01$ ). However this order was reversed in the five year survival rate, indicating that in the patients who did need a

neck dissection (lymph nodes affected) the disease process had been more extensive than in those who did not. In this context the possibility of extra nodal spread must be taken into consideration. Shingaki et al.<sup>(12)</sup> found extra nodal spread to be present in 46% of neck dissection specimens and also they reported that five year survival rate of patients with extra nodal spread was 40% compared to 72% in those without. A feature of extra nodal spread is the increased frequency of distant metastasis. In the present series distant metastasis was detected in only one patient. However this finding is not reliable as the screening for distant metastasis has not been very satisfactory especially in the patients who had died. The possibility that they died due to distant metastasis cannot be ruled out. Therefore, the policy regarding the management of cervical lymph nodes have to be reviewed. Clinical palpability alone may not be a satisfactory criterion.

The frequency of false negative neck nodes could be significantly high when clinical examination was relied upon to detect lymph node metastasis.<sup>(13)</sup> Ishii et al.<sup>(14)</sup> found that ultra sound and CT examination were superior to conventional clinical examination in detecting metastatic nodes. On the other hand Woolgar et al.<sup>(15)</sup> have concluded that the most stringent clinical protocols supplemented by CT scanning cannot be expected to achieve 100% accuracy. They stated that detailed histopathological assessment provides the most reliable currently available method of diagnosing cervical metastatic disease. Thus the Sri Lankan cancer surgeon is in a quandary as to the best approach in the management of cervical lymph nodes. Costly diagnostic methods may not be always available whereas clinical methods may be inadequate.

Another weakness of the study is that the survival rates have not been corrected for age and sex. There was significant difference in the survival rate

between age groups in each gender and also between male and female. However when males and females were taken together there was no significant difference in the three year survival rate between age groups; 40-49, 50-59 and 60-69 to which the large majority (91.6%) of patients belonged.

This study raises more questions than it provides answers. Thus there is a need to study the natural behaviour of oral cancer in Sri Lanka more thoroughly and develop protocols for its accurate diagnosis and adequate treatment.

### References

1. Pinsolle J, Demeaux H, Coustal B, Siberchicot F, Caudry M, Maire J.P. Results of surgical treatment of T3 and T4 Tumours of the oral cavity. *Am J Surg*; 1992; 164 (6): 587-91.
2. Charabi B, Topping H, Kirkegaard J, Hansen H S Oral Cancer – results of treatment in Copenhagen University Hospital. *Acta Otolaryngol Suppl*; 2000; 543:246-7
3. Pradier O, Hummers-Pradier E, Gaci Z, Jadaud D, Descrozailles JM, Gesta P, Germain T Daban A, Hess C F Retrospective analysis of results of treatment of 91 oral cavity cancers from 1982 to 1992. *Cancer Radiother*; 2000; 4 (1): 32.9.
4. El-Husseiny G, Kandil A, Jamshed A, Khafaga Y, Saleem M, Allam A, Al-Rajhi N, Al-Amro A, Rostom A Y, Abuzeid M, Otieschan A, Flores A D. Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors. *Br J Oral maxillofac Surg* 2000; 38(3): 193-9
5. Pericot J, Escriba JM, Valdes A, Biosca M J, Monner A Castellsague X, Galliana R, Piulachs P, Escutia E, Mari A. Survival evaluation of treatment modality in squamous cell carcinoma of the oral cavity and oropharynx. *J Craniomaxillofac Surg* 2000; 28(1): 49-53.
6. Amdur R J, Parsons J T, Mendenhall W H, Million R R., Cassisi N J., Postoperative irradiation for

- squamous cell carcinoma of the head and neck: an analysis of treatment results and complications. *Int J Radiol Oncol Biol Phys*: 1989; 16:25-36.
7. Raybaud H, Fortin A, Bairati I, Morency R, Monteil R A, Tetu B. Nuclear D N A content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma. *Int J Oral Maxillofac. Surg*: 2000; 29:36-41.
  8. Raybaud-Diogene H, Fortin A, Morency R, Roy J, Monteil R A., Tetu B. Markers of radioresistance in squamous cell carcinomas of the head and neck. A clinicopathologic and immunohistochemical study. *J Clin Oncol* 1997; 15:1030-8.
  9. Eneroth CM, Moberger G. Histological grading of malignancy of squamous cell carcinoma of the palate. *Acta Otolaryngol.* 1973; 75:293-295
  10. Willen R, Nathanson A, Moberger G, Anneroth G. Squamous cell carcinoma of the gingiva. Histopathological classification and grading of malignancy. *Acta Otolaryngol.* 1975; 79:146-154
  11. Usama M, Kishi T, Enomoto S, Iwasaki K and Akasaka Y. Malignancy score of primary lesion and metastatic lymph node in squamous cell carcinoma of the tongue. *Asian J Oral Maxillofac Surg.* 1999; 11, (1) 19-29
  12. Shingaki S, Nomura T, Takada M, Kobayashi T, Suzuki I, Nakajima T. The impact of extranodal spread of lymph node metastases in patients with oral cancer. *Int J Oral Maxillofac. Surg.* 1999; 28:279-284
  13. Baatenburg-de-Jong R J, Gullane P G, Freeman J L, . The significance of false-positive nodes in patients with oral cancer. *J Otolaryngol.* 1993; 22 (3): 154-9
  14. Ishii J, Amagasa T, Tachibana T, Shinozuka K, Shioda S. US and CT evaluation of cervical lymph node metastasis from oral cancer. *J Craniomaxillofac Surg.* 1991; 19 (3): 123-7
  15. Woolgar J.A., Beirne J.C, Vaughan E D, Lewis Jones H.G. Scott J. , Brown J.S. Correlation of pathologic findings with clinical and radiologic assessments of cervical lymph node metastases in oral cancer. *Int. J. Oral Maxillofac. Surg* 1995; 24: 30-37.

Tablets

# Dolobid

(Diflunisal, MSD)

500mg

**COUNT ON THE ANALGESIC STRENGTH**

# MSD

**MERCK & CO. INC N.J.U.S.A. 1995**

## **Mansel (Ceylon) Limited**

*Agents for*

- Merck & Co. Inc and subsidiaries

2nd floor AEC Building,  
140, Vauxhall Street,  
Colombo 2.

Telephone : 432897/ 330204  
Email : [mansel@sri.lanka.net](mailto:mansel@sri.lanka.net)  
Fax : 445714

## CASE REPORT

### Cervical mucocele – an unusual presentation of a ranula

S.P.A.G. Ariyawardana and M.A.M. Sitheeque

Department of Oral Medicine and Periodontology, Faculty of Dental Sciences, University of Peradeniya

#### Introduction

The term “ranula” is used to denote a “blue-domed” cystic lesion of the floor of the mouth that has some resemblance to a frog’s belly. Ranulae usually present as unilateral swellings of the floor of the mouth. They have been classified as superficial and deep (plunging).<sup>(1)</sup> A superficial ranula is submucosal and lies entirely above the mylohyoid muscle and the deep ranula lies partly superficial and partly deep to the mylohyoid muscle.<sup>(2)</sup> Intraoral presentation of ranula can be easily recognized as a bluish fluctuant swelling in the floor of the mouth and usually does not pose a diagnostic difficulty.

Plunging ranulae though rare, are well documented as neck swellings.<sup>(3-8)</sup> On some occasions plunging ranulae can occur as extraoral swellings without an associated intraoral swelling.<sup>(5,7)</sup> Such a lesion must be differentiated clinically from a thyroglossal cyst, dermoid cyst, branchial cyst, lymphangioma, laryngocele, lipoma, haemangioma, cyst of the parathyroid and thyroid glands, abscesses or tumours.<sup>(4)</sup> However as specific tests are not available to diagnose ranulae, it may be difficult for a clinician to differentiate it from other extra oral swellings that occur in this region.<sup>(9)</sup>

Histologically, a plunging ranula does not have an epithelial lining. Hence, it is called a pseudocyst. The cyst wall of a ranula is made by compressed fibrous connective tissue containing fibroblasts, vascular channels and inflammatory cells.<sup>(6)</sup>

The treatment of choice for such a cyst is extirpation of the secreting salivary gland via intra-oral route. It is not necessary to excise the cervical extension of the cyst since it does not

contain a true cyst lining.<sup>(4,8)</sup>

This case report describes an unusual presentation of a plunging ranula in that the patient presented only with cervical swelling. The probable pathogenesis is discussed.

#### Case Report

A 16-year-old girl was brought by her parents to the Oral Medicine Clinic, University Dental Hospital, Peradeniya. She had complained of a swelling under the lower jaw on the left side. The swelling was observed over a period of three weeks and had gradually enlarged. In addition, she had noted the enlargement of the swelling during mealtimes. Her past medical history was insignificant. Physical examination revealed that she was a healthy looking well grown girl. There was a swelling of 5 cm in diameter over the submandibular region (Figure 1)

There was no tenderness on palpation and the lesion was fluctuant. The lower border of the mandible was intact. The lesion became more evident when the patient blew her nose which indicated that raised intraoral pressure pushed the lesion into the neck. There was no evidence of intraoral swelling. Fine needle aspiration was carried out and a viscous straw coloured fluid was found. (Figure 2)

Ultrasound scan of the swelling revealed the cystic nature of the swelling (Figure 3)

The diagnosis of a plunging ranula was made and the patient was referred to the Department of Oral Surgery for the extirpation of the sublingual salivary gland of the left side. However, the patient was reluctant to undergo surgery and had got herself discharged.



Figure 1 This photograph shows the lump in the left submandibular region.





Figure 2 The aspiration procedure showing withdrawal of straw-coloured viscous fluid.

### Cervical Mucocele – an unusual presentation of a ranula



3. This photograph of the ultrasound scan shows the cystic nature of the lesion in the submandibular region.

### Discussion

When extra-oral swelling is the only sign, the diagnosis of a plunging ranula poses an obvious problem. There would have been no doubt that the lesion was a plunging ranula if a ranula was evident on the floor of the mouth. However, aspiration of straw coloured viscous saliva from the submandibular swelling led us to think that the swelling was of salivary gland origin. Furthermore, a possibility of haemangioma was eliminated easily due to the colour of the aspirate. Epidermoid or dermoid cysts invariably present as a symmetrical midline swelling, whereas branchial cysts are confined to the lateral neck according to the developmental origin. Therefore, they were excluded from the differential diagnosis. Possibility of an abscess was excluded due to the absence of inflammatory features.

There is little value of sialography and ultrasound

scanning in identifying the origin of a plunging ranula.<sup>(8)</sup> Takimoto<sup>(10)</sup> described a radiological technique in which herniation of a ranula to the neck region could be detected. In this technique radiographs of the submandibular region were taken after injecting 0.5ml of radiopaque medium into the sublingual space. If the contrast medium extends into the neck region on the radiograph, it indicates a plunging ranula. However, this was not possible since the patient was not co-operative for invasive procedures. High protein and amylase levels in the salivary aspirate may pave the way to a diagnosis of a ranula.<sup>(3)</sup> However, in this patient the salivary amylase and protein analyses were not done due to the non-availability of facilities. Therefore, a process of elimination established a probable diagnosis of a plunging ranula herniating through the mylohyoid muscle. However, histopathological diagnosis was not possible since the patient refused surgery.

A plunging ranula develops as a result of

herniation of a ranula through the mylohyoid muscle and along the fascial planes of the neck.<sup>(11)</sup>

However, pathogenesis of plunging ranulae remain controversial. There was considerable debate regarding as to which salivary gland was responsible for the lesion and it is now well established that it originates from the sublingual gland. Roediger et al.<sup>(3)</sup> reported that the development of a plunging ranula is due to the extravasation of mucous from the sublingual gland which ramifies diffusely into the neck. Lyall<sup>(7)</sup> reported that a cervical extension of a ranula appears only when the patient blows his nose or at times while eating. Barnard<sup>(8)</sup> has reported a case of bilateral ranulae that arose asynchronously as cervical swellings.

Gaughran<sup>(12)</sup> described a deficiency or hiatus in the mylohyoid muscle in one third of the population through which a portion of sublingual salivary gland may herniate. Lyall<sup>7</sup> pointed out that certain activities which increase intraoral pressure such as nose blowing, eating and swallowing can encourage herniation of tissues through weak points in the mylohyoid muscle. Therefore, this anomalous herniation of the gland certainly encourages the accumulation of mucous in the submandibular region rather than in the mouth itself.

Furthermore, ectopic sublingual glands superficial to the mylohyoid muscle may also be a source of a cervical ranulae<sup>(9)</sup>, though much attention has not been paid in the literature to this theory. The presence of ectopic sublingual glands or herniation of a part of the sublingual gland was not revealed by the ultrasound report. Furthermore, a surgical verification could not be obtained as the patient refused surgery.

## References

1. Seward GR. Cysts of the salivary glands. In: Shear M. (ed) Cysts of the oral regions. Butterworth-Heinemann, Oxford. 1992; 222 – 256
2. Cawson RA, Binnie WH, Speight PM, Barrett AW, Wright JM. Lucas's pathology of tumours of the oral tissues. Churchill Livingstone. London. 1998; 159- 161
3. Roediger WEW, Lloyd P, Lawson HH. Mucous extravasation theory as a cause of plunging ranulas. Br J Oral Surg 1973; 60(9): 720– 722
4. McClatchey KD, Appelblatt NH, Zarbo RJ, Merrel DM. Plunging ranula. Oral Surg 1984; 57:408 – 412
5. Zafarulla MYM. Cervical mucocele: An unusual case of mucous extravasation cyst. Oral Surg Oral Med Oral Pathol 1986;62: 63-66
6. Skouteris CA, Sotereanos GC. Plunging ranula. J Oral Maxillofac Surg 1987; 45: 1068 – 1072
7. Lyall JB. Plunging ranula: An unusual presentation. Br J Oral Maxillofac Surg 1989; 27: 60-62
8. Barnard NA. Plunging ranula: Bilateral presentation. Br J Oral Maxillofac Surg 1991; 29:112- 113
9. de Visscher JGAM, vander Wall KGH, de Voges PL. The plunging ranula: pathogenesis, diagnosis and management. J Cranio Maxillofac Surg 1989;17: 182 – 184.
10. Takimoto T. Radiographic technique for preoperative diagnosis of plunging ranula. J Oral Maxillofac Surg 1991; 49: 659 –660
11. Regezi JA, Sciubba JJ. Oral Pathology – clinical and pathologic correlations. Saunders. Philadelphia. 1999; 220 –222.
12. Gaughran G RL. Mylohyoid boutonniere and sublingual bouton. J Anat 1963;97(4) 565- 568

## Instructions for Authors

The Sri Lanka Dental Journal publishes the following categories of articles which have relevance to Dentistry and allied sciences.

1. Leading articles – One article per issue. It may be solicited by the Editor. Authors are welcome to submit leading articles on current topics of interest, one's expertise or commentaries on general practice etc. They should be approximately 1500 words in length. References should be 20 or less.
2. Reviews – Reviews are detailed surveys of published research pertinent to dentistry and associated sciences. They should be critical in nature and should not normally exceed 3000 words and 30 references.
3. Research articles – Articles resulting from research work belong to this group. Results from routine clinical examinations or laboratory investigations will not be considered under this category. Subjects may vary from clinical trials to basic science research, historical analysis to dental economics. They should not exceed 3000 words and 30 references. A reasonable number of tables and illustrations will be accepted.
4. Short reports – These include reports on current topics, modified techniques, new materials, practice management etc. Interesting results from routine clinical work or laboratory investigations also may be accepted.
5. Case reports – Reports such as of rare diseases or conditions, modifications to accepted treatment procedures, new management methods etc. may be included in this category.
6. Letters to Editors – Subjects unlimited, but may include short critique of published papers in the SLDJ.
7. Miscellaneous topics – Subjects unlimited and the format are free. These may also include details of scientific meetings, conferences, annual sessions, examinations, news and views, visits and obituaries.

8. Proceedings of annual sessions – Abstracts from annual sessions of the SLDA and other colleges will be published under this category.

### Submission of manuscripts

Authors submitting a paper do so on the understanding that no part has been published before, that it is not being considered for publication elsewhere and that it has been read and approved by all the authors.

Manuscripts including Tables and Figures should be sent in triplicate as the work will be reviewed by two or more referees. While papers are subject to editing, the journal does not hold it responsible for statements made by the contributor. The author alone is responsible for the statements made in his paper.

Submission of a manuscript means that authors automatically agree to assign exclusive copyright to the Sri Lanka Dental Association if and when the manuscript is accepted for publication.

### Manuscript on disk

Once an article has been accepted for publication, the author will be asked to supply a copy of the final manuscript on disk together with two copies of the complete manuscript. Every disk must be clearly labelled with the name of the author, title, software and program version number.

### Manuscript style

The manuscripts should be typed, double-spaced, on A4 (212x297 mm) paper and submitted in correct English; both English and American spelling are acceptable, provided this is consistent throughout the manuscript. Manuscripts not submitted in proper format or in poor English may be returned without review. The format of a manuscript should be as

follows: Title page, Abstract, Introduction, Material and methods, Results, Discussion, Acknowledgements, References, Figure legends, and Tables, arranged in that order.

**Title page** - The title page should contain the following information in the order given: 1) a concise but informative title; 2) author's full names (without degrees and titles); 3) author's institutional affiliations; 4) a running title, not exceeding 40 letters and spaces; 5) name, address, telephone, telefax and electronic mail address of the author responsible for correspondence.

**Abstract page** - Original and review articles must contain an abstract of approximately 250 words with four specified subtitles:

- 1) **Objective:** An introductory sentence indicating the objective and purpose of the study.
- 2) **Material and methods:** A description of experimental procedure including applicable statistical evaluation.
- 3) **Results:** A summary of the new, previous unpublished data and results.
- 4) **Conclusion:** A statement of the study's conclusion 3-5 key words according to Index Medicus should be provided.

**Introduction** - The introduction should carry sufficient background information on the subject of study.

**Material and methods** - Procedures should be described in such detail as to make it possible to repeat the work. Subheadings may be used to improve clearness. Correct unit abbreviations should be used (e.g.; "h", "min", "s" and "µm" rather than "hr", "minutes", "sec" and "µ", respectively).

The authors should consider the ethical aspects of their research and ensure that the work has been approved by an appropriate Ethical Committee. Where applicable,

a copy of the ethical clearance certificate should be attached. In human experimentation, informed consent from individuals should be obtained and this should preferably be stated.

**Statistical analysis** - Since many scientific investigations rely on statistical treatment, authors are strongly urged to consult a person with in-depth statistical knowledge. Manuscripts with a clear element of statistics are regularly refereed by the Journal's statistics consultant.

**Results** - The Results section should clearly and concisely present the findings of the research, as a rule in the past tense without subjective comments and reference to previous literature. The results should be supported by statistical or illustrative validation. For the sake of clarity this section may have subheadings.

**Discussion** - This section should present the interpretations of the findings and is the only proper section for subjective comments. Authors are strongly urged to avoid undue repetition of what has been reported in Results.

**Tables** - The tables should be numbered in the order of appearance in Arabic numerals. Each table should have a brief explanatory title. Each table should be typed on a separate sheet, with due regard to the proportion of the printed column/page.

**Figures** - All graphs, drawings, and photographs are considered figures and should be numbered in the order of appearance in Arabic numerals. Each figure should have a brief and specific legend, and all legends should be typed together on a separate sheet of paper. Photographs should be glossy prints and the reverse should give the figure number, title of paper principal author's name and have a mark indicating the top. Colour illustrations may be submitted in instances where their use may contribute significantly to the scientific value of the article. Colour illustrations may be printed free of charge at the Editor's discretion, whereas others may be printed at the author's expense.

**References** - References are listed double-spaced in a separate reference section immediately following the text. References are numbered consecutively in the order in which they appear in the text; do not alphabetise. Identify references in texts, tables and legends by Arabic numerals (within parenthesis).

Congress abstracts should not be used as references nor may "unpublished observations" and "personal communications" be placed in the reference list. References cited as "in press" must have been accepted for publication and not merely in preparation or submitted for publication

Examples of correct forms of references are given below. These are based on the format used in the *Index Medicus*. Abbreviate journal names according to the *List of Journals Indexed*, printed annually in the January issue of *Index Medicus*. List all authors; do not use *et al.* in the reference list.

#### **Journals**

Standard journal article

Bartlett JG, O'Keefe P. The bacteriology of the perimandibular space infections. *J Oral Surg* 1979; 37: 407-409.

Corporate (collective) author

WHO COLLABORATING CENTRE FOR ORAL PRECANCEROUS LESIONS. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. *Oral Surg Oral Med Oral Pathol* 1978; 46: 518-539.

Unpublished article

Barker DS, Lucas RB. Localised fibrous growth of the oral mucosa. *J Dent Res* 1965; in press.

Books and other monographs

Pindborg JJ. Atlas of diseases of the oral mucosa. 5<sup>th</sup> edition. Copenhagen: Munksgaard, 1992; 50-66.

Chapter in book

Boyde A. Amelogenesis and the structure of enamel. In: Cohen B, Kramer KH (eds). *Scientific Foundations of Dentistry*. William Heinemann Medical Books Ltd. London, 1976; 335-352.

No author given

International statistical classification of diseases and related health problems, 10<sup>th</sup> revision, vol 1. Geneva: World Health Organisation, 1992; 550-564

## **YU AND COMPANY PTE LTD.**

The supplier of quality Dental equipment.

### **CURING LIGHT**

#### **SPECIFICATION:**

- Power Source: 115V~230V~ 50/60Hz, Weight 2.5 kg. 75 watt, 12V, halogen curing lamp.
- 8mm Light guide with 360-degree rotation and can be autoclavable.
- Computer control on/off interval of lamp to protect and lengthen the using period of it.
- Individual curing time selection with beep tone signal.
- In built cooling fan in light gun with automatical turning off, of the fan after cool down period. Fuse and thermal cut-off switch to prevent overheating. Oval protector to protect doctor's eyes from intense light.

### **ULTRASONIC SCALER**

#### **SPECIFICATIONS:**

- Power Source 115V~230V – 50/60 Hz, Weight 2.1 kg.
- 31.5 KHz + 0.5 powerful energy to remove stubborn calculus and stains.
- Tuning control on power supply and water spray.
- T1 Hand piece will not heat up even with incessant usage.
- Refined tips with high quality in substance and shape.
- Low-pressure water inlet (no pressure tank needed). 1 Wrench, 1 Pedal, 1 Power Cable.

### **MICRO MOTOR WITH CARRY CASE**

#### **SPECIFICATIONS:**

- E-type Straight Hand piece (25,000 rpm). E-type Conrtriangle Hand piece (20,000 rpm).
- Foot Control with long cable. Carry Case with handle. Autoclavable Hand Piece
- Control unit – 60mm H X 80mm W X 147mm D. Power input 110 ~ 230V AC 50 Hz. Variable speeds from 1500 rpm – 25,000 rpm. On/off and forward/reverse switches on the control box.
- 1 Micro motor with spring type cable (25,000 rpm).

### **DENTAL CHAIR AND UNIT**

#### **SPECIFICATIONS:**

- Electrically controlled dental chair with buttons to control movements. (Up, down, incline and recline).
- 2 Air terminals for hand pieces with water control. 1 Dental Light with 20,000 Lux intensity.
- 1 Triple syringe (Water, air and spray). 1 Porcelain Spittoon with water flush.
- 2 Cup holders with refill tap. 1 Air operated saliva ejector. 1 Air operated high suction aspirator.
- 1 High speed (400,000 rpm) push button chuck type air rotor conrtriangle hand piece.
- 1 Air motor unit with forward and reverse (30,000 rpm).
- 1 E-type straight Hand Piece for air motor (30,000 rpm).
- 1 E-type conrtriangle Hand Piece for air motor (20,000 rpm).
- Bio system to avoid reflex of contaminated material with the ability to flush the hand piece cables.

### **OIL FREE AIR COMPRESSOR**

#### **SPECIFICATIONS:**

- Tank Capacity 25 liters. Air delivery 200 lit/minute. Max pressure 116 PSI. Minimum Pressure 80 PSI.
- Motor Power 2 HP direct drive. Power Input 230 volts 50 hertz (single phase).

**Call us or drop in at our office for prices or product demonstration.**

**Address: 167 Olcott Mawatha Colombo 11.**


**Tel: 431371, 470334 Fax: 422729 Email: fusan@slt.lk**

**"TRIPLE  
ACTION"**

**"Pyralvex<sup>®</sup>**

- \* analgesic
- \* anti-inflammatory
- \* antibacterial

**THE solution for  
painful mouths"**



**PRODUCT INFORMATION**

**PRESENTATIONS:**

Pyralvex Solution: Bottle containing 10ml solution with brush.  
Pyralvex Gel: Tube containing 15g gel.

**CONTENTS:**

Each 1ml of solution or 1g of gel contains 0.05g rhubarb extract (equiv. to 0.003g anthraquinone glycosides).  
0.01g salicylic acid BP.

**INDICATIONS:**

Gingivitis, stomatitis, ulcers of the mouth. Inflammation of the oral mucosa. Inflammatory periodontal conditions. In all the above conditions, Pyralvex may be used alone or as an adjunct to systemic chemotherapy or dental treatment.

**DIRECTIONS FOR USE:**

Apply Pyralvex paint with the brush provided (after removing any dentures). The gel should be applied with the clean tip of a finger. Pyralvex should be applied 3 or 4 times daily or as directed by the doctor or dentist. Do not rinse the mouth for at least 15 minutes.

**REFERENCES:**

1. Chaput A., L'information Dentaire 10 (1964).
2. Galletti F.P., Rivista Italiana di Stomatologia 7 (1965).
3. Rengglis H., Schweiz Mschr Zahnheilk 90, 8 782, (1980).

HEMAS PHARMACEUTICALS (PTE) LIMITED  
HEMAS BUILDING, 36, BRISTOL STREET, P.O. BOX: 911, COLOMBO 1  
TEL: 541095, 448320, 328796, 332241, 422307-8, 437394-5  
FAX: 437695 E-mail: hmpharma@sri.lanka.net



NORGINE LIMITED  
CHAPLIN HOUSE WIDEWATER PLACE  
MOORHALL ROAD HAREFIELD  
UXBRIDGE MIDDLESEX UB9 6NS  
UNITED KINGDOM.

\* NORGINE AND PYRALVEX ARE TRADEMARKS



*I'm happy  
I deal with  
UNICEL .....*



**UNICEL**  
**(PRIVATE) LIMITED**

ARC ADVERTISING

**acknowledged by Dentists in Sri Lanka  
as a reliable source for Dental Products  
for over three decades.....**

25, Hedges Court, Colombo 10, Sri Lanka.  
Phone: 94-1-699765, 686848 Fax: 94-1-697097, 686848

*Sole Agents in Sri Lanka for:* \_\_\_\_\_

**IVOCLAR-VIVADENT  
DENTAURUM**


**MEADWAY  
RIVERSIDE**

**YOSHIDA  
HATAKEYAMA**

**MANI INC.  
DENCARE**

BEFORE A HEART ATTACK

AFTER A HEART ATTACK



*With a sum assured of upto Rs. 2 million covering 25 illnesses.*

*Plus the advantage of low premiums for non-smokers.*

*And efficiency in claim settlement. All these  
make SUWAMAGA the healthiest policy in Sri Lanka.*



**UNION SUWA MAGA**  
CRITICAL ILLNESS COVER

Union Assurance Centre, 20, St. Michael's Road, Colombo 3. Tel: 438161-4 Fax: 438165 Internet: <http://www.unionassurance.com>

HEXAS

*With Compliments  
from*



# Clogard



*Protects Teeth, Freshens Breath*

# As the dental care leader in Sri Lanka,

# **Signal** DOUBLE ACTION

## has several firsts to its credit

**1**st to introduce a clinically proven toothpaste in Sri Lanka.

**1**st to launch Fluoride toothpaste in Sri Lanka.

**1**st to introduce a superior Fluoride system.

**1**st to bring the innovative 3 angled toothbrush.

**1**st to be professionally recommended by the Sri Lanka Dental Association (SLDA).

**1**st to conduct islandwide dental support programmes for school children.

**1**st to organise mobile outreach programmes for village communities through mobile dental clinics, dental seminars and educational exhibitions.

**1**st to promote an International Dental Congress in Sri Lanka.

